BLOOD CANCER UNITED INC: Form 990, tax year 2014

View the entire original 990 at ProPublica ↗

Organization
BLOOD CANCER UNITED INC (EIN 13-5644916)
Tax period
2014-07-01 to 2015-06-30
Filed
2016-02-11
IRS object ID
201620429349300232
Schema version
2014v6.0
Source
Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header ReturnHeader

FieldValueIRS element (for citing)
Return2016-02-11T09:16:30-06:00ReturnTs
Tax Period End2015-06-30TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

FieldValueIRS element (for citing)
Preparer Firm EIN135565207PreparerFirmEIN

Preparer Firm Name PreparerFirmName

FieldValueIRS element (for citing)
Business Name Line1KPMG LLPBusinessNameLine1Txt

Preparer US Address PreparerUSAddress

FieldValueIRS element (for citing)
Address Line1345 PARK AVENUEAddressLine1Txt
CityNEW YORKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP101540102ZIPCd
FieldValueIRS element (for citing)
Return Type990ReturnTypeCd
Tax Period Begin2014-07-01TaxPeriodBeginDt

Filer Filer

FieldValueIRS element (for citing)
EIN135644916EIN

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1THE LEUKEMIA & LYMPHOMA SOCIETYINCBusinessNameLine1Txt
FieldValueIRS element (for citing)
Business Name ControlLEUKBusinessNameControlTxt
Phone9149495213PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line11311 MAMARONECK AVENUE - SUITE 310AddressLine1Txt
CityWHITE PLAINSCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10605ZIPCd

Business Officer BusinessOfficerGrp

FieldValueIRS element (for citing)
PersonROSEMARIE LOFFREDOPersonNm
Person TitleEVP - CAO & CFOPersonTitleTxt
Phone9149495213PhoneNum
Signature2016-02-09SignatureDt
Discuss With Paid PreparerYes (true)DiscussWithPaidPreparerInd

Preparer Person PreparerPersonGrp

FieldValueIRS element (for citing)
Preparer PersonKPMG LLPPreparerPersonNm
PTINP01249521PTIN
Phone2127589700PhoneNum
Preparation2016-02-11PreparationDt
FieldValueIRS element (for citing)
Tax2014TaxYr
Build TS2016-08-17 19:52:53ZBuildTS

Form 990 IRS990

FieldValueIRS element (for citing)
Principal OfficerLOUIS J DEGENNARO PRESIDENT CEOPrincipalOfficerNm

US Address USAddress

FieldValueIRS element (for citing)
Address Line11311 MAMARONECK AVENUEAddressLine1Txt
CityWHITE PLAINSCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10605ZIPCd
FieldValueIRS element (for citing)
Gross Receipts$387,950,949GrossReceiptsAmt
Group Return For AffiliatesfalseGroupReturnForAffiliatesInd
Organization501c3Yes (X)Organization501c3Ind
Website AddressWWW.LLS.ORGWebsiteAddressTxt
Type Of Organization CorpYes (X)TypeOfOrganizationCorpInd
Formation1949FormationYr
Legal Domicile StateNYLegalDomicileStateCd
Activity Or MissionOUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES.ActivityOrMissionDesc
Voting Members Governing Body29VotingMembersGoverningBodyCnt
Voting Members Independent29VotingMembersIndependentCnt
Total Employee1321TotalEmployeeCnt
Total Volunteers3000000TotalVolunteersCnt
Total Gross UBI$0TotalGrossUBIAmt
PY Contributions Grants$302,437,152PYContributionsGrantsAmt
CY Contributions Grants$283,909,984CYContributionsGrantsAmt
CY Program Service Revenue$0CYProgramServiceRevenueAmt
PY Investment Income$6,995,117PYInvestmentIncomeAmt
CY Investment Income$4,913,321CYInvestmentIncomeAmt
PY Other Revenue$663,718PYOtherRevenueAmt
CY Other Revenue-$7,194,375CYOtherRevenueAmt
PY Total Revenue$310,095,987PYTotalRevenueAmt
CY Total Revenue$281,628,930CYTotalRevenueAmt
PY Grants And Similar Paid$130,249,475PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid$107,996,054CYGrantsAndSimilarPaidAmt
CY Benefits Paid To Members$0CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid$94,185,722PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid$85,679,493CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns$7,178,370PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns$4,709,809CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense$42,413,663CYTotalFundraisingExpenseAmt
PY Other Expenses$85,584,715PYOtherExpensesAmt
CY Other Expenses$79,057,701CYOtherExpensesAmt
PY Total Expenses$317,198,282PYTotalExpensesAmt
CY Total Expenses$277,443,057CYTotalExpensesAmt
PY Revenues Less Expenses-$7,102,295PYRevenuesLessExpensesAmt
CY Revenues Less Expenses$4,185,873CYRevenuesLessExpensesAmt
Total Assets BOY$242,581,527TotalAssetsBOYAmt
Total Assets EOY$214,485,806TotalAssetsEOYAmt
Total Liabilities BOY$145,444,419TotalLiabilitiesBOYAmt
Total Liabilities EOY$116,963,860TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY$97,137,108NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY$97,521,946NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part IIIYes (X)InfoInScheduleOPartIIIInd
MissionOUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES.MissionDesc
Significant New Program SrvcfalseSignificantNewProgramSrvcInd
Significant ChangefalseSignificantChangeInd
Expense$69,238,255ExpenseAmt
Grant$65,760,793GrantAmt
DescA) RESEARCH PROGRAMS: WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, LLS FUNDS EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVED OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS, AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. LLS IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE. TO DATE, LLS HAS INVESTED OVER 1 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2015, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 7 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 65 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, AND, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. - ADCETRIS WAS APPROVED IN 2011, AND IN JANUARY 2012. IT IS AN ANTIBODY- DRUG CONJUGATE THAT COMBINES AN ANTI-CD30 ANTIBODY AND THE CYTOTOXIC DRUG MONOMETHYL AURISTATIN E (MMAE). IT IS AN ANTI-NEOPLASTIC AGENT USED IN THE TREATMENT OF HODGKIN LYMPHOMA AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT OR THOSE WHO ARE NOT ELIGIBLE FOR ASCT AFTER FAILURE OF AT LEAST 2 MUTIAGEN CHEMOTHERAPY REGIMENS. ADCETRIS WAS ALSO APPROVED FOR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA WITH FAILURE OF AT LEAST ONE PRIOR TREATMENT. - GAZYVA IS A HUMANIZED MONOCLONAL ANTIBODY USED AS A COMBINATION TREATMENT WITH CHLORAMBUCIL TO TREAT PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. IT WAS APPROVED BY THE FDA IN NOVEMBER 2013 AND BY THE EHA IN JULY 2014. - IMBRUVICA IS AN ORAL SMALL MOLECULE INHIBITOR AGIANST BTK KINASE. IT WAS FIRST APPROVED BY THE US FDA ON NOVEMBER 13, 2013 FOR THE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS WHO HAVE RECIEVED AT LEAST ONE PRIOR TREATMENT. ON FEB. 12, 2014 THE US FDA EXPANDED THE APPROVED USE OF THE DRUG TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ADDITIONALLY, IT RECEIVED FURTHER EXPANSION TO TREAT 17P DELETION IN CLL WITH OR WITHOUT PRIOR THERAPY. - ZYDELIG IS AN ORAL SMALL MOLECULE INHIBITOR THAT BLOCKS THE DELTA ISOFORM OF THE ENZYME PHOSPHOINOSITIDE 3-KINASE. IT WAS APPROVED BY THE FDA IN JULY 2014 TO TREAT RELAPSED/REFRACTORY CLL IN COMBINATION WITH RITUXAN. IT WAS ALSO APPROVED TO USE AS A MONOTHERAPY FOR RELAPSED MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2015, FOR THE FOURTH YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN SIX OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR PATIENTS WITH NON- CUTANEOUS T-CELL LYMPHOPROLIFERATIVE DISORDERS - DEVELOP NOVEL TARGETED THERAPIES FOR CLL PATIENTS, WITH REAL CURATIVE POTENTIAL - DEVELOP NOVEL TREATMENT STRATEGIES FOR MDS AND AML PATIENTS - DEVELOP NOVEL TARGETED THERAPIES FOR PATIENTS WITH HIGH-RISK MYELOMA - DEVELOPMENT OF NEW-TARGETED THERAPIES FOR INDOLENT LYMPHOMA PATIENTS - DEFINE GENETIC/MOLECULAR PREDISPOSITIONS TO LONG-TERM AND LATE-Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

FieldValueIRS element (for citing)
Expense$86,747,069ExpenseAmt
Grant$42,235,261GrantAmt
DescB) PATIENT & COMMUNITY SERVICES: AN ESTIMATED 1.2 MILLION PEOPLE ACROSS THE UNITED STATES (US) CURRENTLY BATTLE LEUKEMIA, LYMPHOMA AND MYELOMA. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) OFFERS A FREE, COMPREHENSIVE ARRAY OF SERVICES TO BLOOD CANCER PATIENTS AND THEIR FAMILIES, VOLUNTEER CAREGIVERS AND ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. LLS IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION. PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH LLS STAFF TO REVIEW ALL OF THE INFORMATION LLS PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL; AND CURRENT AND ACCURATE INFORMATION ABOUT SYMPTOMS, RISK FACTORS AND TREATMENT. PUBLICATIONS AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS THROUGH THE INFORMATION RESOURCE CENTER AND LLS CHAPTERS. MANY MATERIALS ARE ALSO AVAILABLE TO VIEW AND DOWNLOAD AT WWW.LLS.ORG/RESOURCECENTER. DOWNLOADABLE MATERIALS ARE AVAILABLE IN ENGLISH, SPANISH AND FRENCH. - 705,326 PRINTED BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS DISTRIBUTED IN 2015. FINANCIAL ASSISTANCE IN 2015, A COMBINED 42,235,261 WAS DISBURSED TO PATIENTS THROUGH THE LLS PATIENT FINANCIAL AID (111,525),CO-PAY ASSISTANCE PROGRAMS (41,805,481) AND THE LLS NATIONAL PATIENT TRAVEL ASSISTANCE PROGRAM (318,255). CO-PAY ASSISTANCE PROGRAM THIS CO-PAY ASSISTANCE PROGRAM HELPS PATIENTS WITH MANY KINDS OF BLOOD CANCERS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO-PAYMENT OBLIGATIONS RELATED TO TREATING THEIR CANCER. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUND AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. FOR MORE INFORMATION CALL, (877) LLS-COPAY (877) 557-2672 OR VISIT WWW.LLS.ORG/COPAY. - 19,922 PATIENTS RECEIVED LLS CO-PAY ASSISTANCE IN 2015 COMMUNITY PROGRAMS EACH LLS CHAPTER OFFICE IS STAFFED WITH A PATIENT SERVICES MANAGER (PSM) WHO OVERSEES SERVICES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PSMS ARE HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING OR SOCIAL WORK. PSMS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS. COMMUNITY-BASED EDUCATION AND OUTREACH, SUPPORT AND PUBLIC POLICY AND ADVOCACY PROGRAMS ARE AVAILABLE. PATIENT EDUCATION PROGRAMS: IN 2015 WE CONDUCTED 221 LOCAL PATIENT EDUCATION PROGRAMS TO A TOTAL OF 9,807 ATTENDEES. THESE PROGRAMS RANGED FROM DISEASE SPECIFIC TOPICS TO THOSE OF SURVIVORSHIP. OF THE TOTAL ATTENDING THESE LOCAL EDUCATION PROGRAMS, A MAJORITY WERE PATIENTS AND CAREGIVERS (6,872 ATTENDEES) BUT IMPORTANTLY, MANY (2,404 ATTENDEES) WERE HEALTHCARE PROFESSIONALS. BLOOD CANCER CONFERENCES: LLS WORKS TO ELEVATE OUR VISIBILITY IN COMMUNITIES WE SERVE BY HOSTING LARGER-SCALE CONFERENCES, GEARED FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. THESE EVENTS ARE A CATALYST FOR BRINGING MANY DEDICATED PEOPLE TOGETHER TO FOCUS ON BLOOD CANCER AWARENESS, INFORMATION AND THE LATEST ADVANCES IN MEDICAL SCIENCE. THEY ARE ALSO AN IMPORTANT SOURCE OF CONTINUING EDUCATION FOR MANY HEALTHCARE PROFESSIONALS. IN 2015, 25 BCC CONFERENCES WERE HELD WITH TOTAL ATTENDANCE OF 6,589. 2,965 WERE PATIENTS, 1,511 CAREGIVERS, 1,001 NURSES, 181 SOCIAL WORKS, 128 MEDICAL DOCTORS, AND 628 "OTHER" HEALTHCARE PROFESSIONALS SERVING THE UNDERSERVED: IN 2015, WE OFFERED 68 SPECIAL PROGRAMS TO PEOPLE WHO OFTEN DON'T HAVE THE SAME ACCESS TO INFORMATION AND SUPPORT AS OTHERS MIGHT HAVE. BREAKING DOWN ACCESS BARRIERS IN UNDERREPRESENTED POPULATIONS MEANS BLOOD CANCER PATIENTS GET THE INFORMATION AND SUPPORT THEY NEED. THIS OUTREACH BROUGHT IMPORTANT DISEASE TREATMENT INFORMATION TO MORE THAN 5,500 PEOPLE IN COMMUNITIES WE SERVE. OF THIS, 3,870 WERE PATIENTS AND CAREGIVERS, JOINED BY 1,126 HEALTHCARE PROFESSIONALS. MYELOPROLIFERATIVE NEOPLASMS OR MPN: IN 2015, LLS WAS ABLE TO OFFER SPECIALIZED MYELOPROLIFERATIVE NEOPLASMS OR MPN EDUCATION PROGRAMS IN FOUR COMMUNITIES TO A TOTAL OF 70 PATIENTS AND CAREGIVERS AND 9 HEALTHCARE PROFESSIONALS. IN ADDITION, LLS PROVIDED COMMUNITY-BASED EDUCATION CONCERNING THE LATEST CLINICAL TRIALS INFORMATION TO 634 PATIENTS AND CAREGIVERS, WHO WERE JOINED BY 286 HEALTHCARE PROFESSIONALS. FAMILY SUPPORT GROUPS: THROUGHOUT THE US, IN 2015, LLS SUPPORTED OR HOSTED 296 REGISTERED FAMILY SUPPORT GROUP MEETINGS FOR PATIENTS AND THEIR FAMILIES. GROUPS ARE GUIDED BY TWO VOLUNTEER ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. LLS SUPPORT GROUPS ARE THE PERFECT PLACE TO TALK WITH OTHER PEOPLE AFFECTED BY BLOOD CANCERS, INCLUDING PATIENTS, FAMILY MEMBERS AND CAREGIVERS. THE GROUPS PROVIDE MUTUAL SUPPORT AND OFFER THE OPPORTUNITY TO DISCUSS ANXIETIES AND CONCERNS WITH OTHERS WHO SHARE THE SAME EXPERIENCES. THIS SHARING STRENGTHENS THE FAMILY BOND AND ENHANCES EVERYONE'S ABILITY TO COPE WITH CANCER. PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM: FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT-VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE NEW PATIENT TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS. - 1,476 FIRST CONNECTIONS ACROSS THE US IN 2015.Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

FieldValueIRS element (for citing)
Expense$33,246,948ExpenseAmt
DescC) PUBLIC HEALTH EDUCATION: INFORMATION AND EDUCATION. INFORMATION RESOURCE CENTER. PAYING FOR MEDICAL CARE, MAKING TREATMENT CHOICES, COMMUNICATING WITH HEALTHCARE PROVIDERS, FAMILY MEMBERS AND FRIENDS-THESE ARE SOME OF THE STRESSES THAT COME WITH A CANCER DIAGNOSIS. LLS INFORMATION SPECIALISTS ARE MASTER'S LEVEL ONCOLOGY SOCIAL WORKERS, NURSES AND HEALTH EDUCATORS WHO PROVIDE HELP WITH DISEASE, TREATMENT AND CLINICAL TRIAL INFORMATION AND SUPPORT. LLS INFORMATION SPECIALISTS CONDUCT CLINICAL-TRIAL SEARCHES TO HELP PATIENTS WORK WITH THEIR DOCTORS TO FIND OUT ABOUT SPECIFIC CLINICAL TRIALS. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 9 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. - 31,511 INQUIRIES MADE TO OUR INFORMATION SPECIALISTS, AND 30,871 INQUIRIES MADE TO OUR PATIENT ACCESS STAFF ACROSS THE COUNTRY IN 2015. THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO THEIR LOCATION TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING CO-PAY ASSISTANCE, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH AND SPANISH, AND CLINICAL-TRIAL SEARCHES VIA AN ONLINE CLINICAL- TRIAL SEARCH SERVICE THAT OFFERS PATIENTS AND CAREGIVERS IMMEDIATE ACCESS TO LISTINGS OF BLOOD CANCER CLINICAL TRIALS. PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS CAN INTERACT WITH LLS AND ONE ANOTHER THROUGH SOCIAL NETWORKING, PODCASTS AND ENEWSLETTERS. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS LLS SPONSORS TELEPHONE AND WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES. IN 2015, 9 LLS NATIONAL EDUCATION PROGRAMS FEATURED DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT SUPPORT AND TREATMENT OPTIONS FROM WORLD RENOWNED CLINICAL EXPERTS. OPPORTUNITIES ARE PROVIDED TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. THESE PROGRAMS OFFER CONTINUING EDUCATION CREDITS FOR NURSES AND SOCIAL WORKERS. LLS ALSO SPONSORS A RANGE OF PROFESSIONAL EDUCATION PROGRAMS. RECENT PROGRAMS EXPLORED THE ADMINISTRATION AND MANAGEMENT OF CURRENT THERAPIES FOR HEMATOLOGIC MALIGNANCIES AND COMMUNICATION AMONG PRIMARY CARE PROVIDERS AND HEMATOLOGISTS/ONCOLOGISTS IN MANAGING PATIENTS WITH HEMATOLOGIC CANCER. UPCOMING PROGRAMS ARE POSTED AT WWW.LLS.ORG/PROGRAMS AND ARCHIVES OF PAST PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PASTPROGRAMS. PROFESSIONAL EDUCATION PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PROFESSIONALED. LLS ALSO OFFERS DISEASE-SPECIFIC WEBCASTS PRESENTED BY WORLD RENOWNED CLINICAL EXPERTS. THESE CAN BE ACCESSED AT WWW.LLS.ORG/WEBCASTS.Desc

Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp

FieldValueIRS element (for citing)
Expense$16,562,341ExpenseAmt
DescD) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT.Desc
FieldValueIRS element (for citing)
Total Other Prog Srvc Expense$16,562,341TotalOtherProgSrvcExpenseAmt
Total Program Service Expenses$205,794,613TotalProgramServiceExpensesAmt
Described In Section501c3Yes (true)DescribedInSection501c3Ind
Schedule B RequiredYes (true)ScheduleBRequiredInd
Political Campaign ActyfalsePoliticalCampaignActyInd
Lobbying ActivitiesYes (true)LobbyingActivitiesInd
Subject To Proxy TaxfalseSubjectToProxyTaxInd
Donor Advised FundfalseDonorAdvisedFundInd
Conservation EasementsfalseConservationEasementsInd
Collections Of ArtYes (true)CollectionsOfArtInd
Credit CounselingfalseCreditCounselingInd
Temp Or Permanent EndowmentsYes (true)TempOrPermanentEndowmentsInd
Report Land Building EquipmentYes (true)ReportLandBuildingEquipmentInd
Report Investments Other SecYes (true)ReportInvestmentsOtherSecInd
Report Program Related InvstfalseReportProgramRelatedInvstInd
Report Other AssetsfalseReportOtherAssetsInd
Report Other LiabilitiesfalseReportOtherLiabilitiesInd
Include FIN48 FootnoteYes (true)IncludeFIN48FootnoteInd
Independent Audit Fincl StmtfalseIndependentAuditFinclStmtInd
Consolidated Audit Fincl StmtYes (true)ConsolidatedAuditFinclStmtInd
School OperatingfalseSchoolOperatingInd
Foreign OfficeYes (true)ForeignOfficeInd
Foreign ActivitiesYes (true)ForeignActivitiesInd
More Than5000 K To OrgYes (true)MoreThan5000KToOrgInd
More Than5000 K To IndividualsfalseMoreThan5000KToIndividualsInd
Professional FundraisingYes (true)ProfessionalFundraisingInd
Fundraising ActivitiesYes (true)FundraisingActivitiesInd
Gaming ActivitiesYes (true)GamingActivitiesInd
Operate HospitalfalseOperateHospitalInd
Grants To OrganizationsYes (true)GrantsToOrganizationsInd
Grants To IndividualsYes (true)GrantsToIndividualsInd
Schedule J RequiredYes (true)ScheduleJRequiredInd
Tax Exempt BondsfalseTaxExemptBondsInd
Engaged In Excess Benefit TransfalseEngagedInExcessBenefitTransInd
PY Excess Benefit TransfalsePYExcessBenefitTransInd
Loan OutstandingfalseLoanOutstandingInd
Grant To Related PersonfalseGrantToRelatedPersonInd
Business Rln With Org MemfalseBusinessRlnWithOrgMemInd
Business Rln With Fam MemfalseBusinessRlnWithFamMemInd
Business Rln With Officer EntfalseBusinessRlnWithOfficerEntInd
Deductible Non Cash ContriYes (true)DeductibleNonCashContriInd
Deductible Art ContributionfalseDeductibleArtContributionInd
Terminate OperationsfalseTerminateOperationsInd
Partial LiquidationfalsePartialLiquidationInd
Disregarded EntityfalseDisregardedEntityInd
Related EntityYes (true)RelatedEntityInd
Related Organization Ctrl EntYes (true)RelatedOrganizationCtrlEntInd
Transaction With Control EntYes (true)TransactionWithControlEntInd
Trnsfr Exmpt Non Chrtbl Rltd OrgfalseTrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted PrtshpfalseActivitiesConductedPrtshpInd
Schedule O RequiredYes (true)ScheduleORequiredInd
IRP Document845IRPDocumentCnt
IRP Document W2 G23IRPDocumentW2GCnt
Backup Wthld ComplianceYes (true)BackupWthldComplianceInd
Employee1321EmployeeCnt
Employment Tax Returns FiledYes (true)EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over LimitfalseUnrelatedBusIncmOverLimitInd
Foreign Financial AccountYes (true)ForeignFinancialAccountInd
Foreign CountryCAForeignCountryCd
Prohibited Tax Shelter TransfalseProhibitedTaxShelterTransInd
Taxable Party NotificationfalseTaxablePartyNotificationInd
Nondeductible ContributionsfalseNondeductibleContributionsInd
Quid Pro Quo ContributionsYes (true)QuidProQuoContributionsInd
Quid Pro Quo Contri DisclYes (true)QuidProQuoContriDisclInd
Form8282 Property Disposed OffalseForm8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft CntrctfalseRcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft CntrctfalsePayPremiumsPrsnlBnftCntrctInd
Indoor Tanning ServicesfalseIndoorTanningServicesInd
Info In Schedule O Part VIYes (X)InfoInScheduleOPartVIInd
Governing Body Voting Members29GoverningBodyVotingMembersCnt
Independent Voting Member29IndependentVotingMemberCnt
Family Or Business RlnfalseFamilyOrBusinessRlnInd
Delegation Of Mgmt DutiesfalseDelegationOfMgmtDutiesInd
Change To Org DocumentsfalseChangeToOrgDocumentsInd
Material Diversion Or MisusefalseMaterialDiversionOrMisuseInd
Members Or StockholdersYes (true)MembersOrStockholdersInd
Election Of Board MembersYes (true)ElectionOfBoardMembersInd
Decisions Subject To ApprovaYes (true)DecisionsSubjectToApprovaInd
Minutes Of Governing BodyYes (true)MinutesOfGoverningBodyInd
Minutes Of CommitteesYes (true)MinutesOfCommitteesInd
Officer Mailing AddressfalseOfficerMailingAddressInd
Local ChaptersYes (true)LocalChaptersInd
Policies Reference ChaptersYes (true)PoliciesReferenceChaptersInd
Form990 Provided To Gvrn BodyYes (true)Form990ProvidedToGvrnBodyInd
Conflict Of Interest PolicyYes (true)ConflictOfInterestPolicyInd
Annual Disclosure Covered PrsnYes (true)AnnualDisclosureCoveredPrsnInd
Regular Monitoring EnfrcYes (true)RegularMonitoringEnfrcInd
Whistleblower PolicyYes (true)WhistleblowerPolicyInd
Document Retention PolicyYes (true)DocumentRetentionPolicyInd
Compensation Process CEOfalseCompensationProcessCEOInd
Compensation Process OtherfalseCompensationProcessOtherInd
Investment In Joint VenturefalseInvestmentInJointVentureInd
States Where Copy Of Return Is FldAKStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldALStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldARStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldAZStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCOStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCTStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldDEStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldDCStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldFLStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldGAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldHIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldIDStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldILStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldINStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldKSStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldKYStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldLAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMDStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMEStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMNStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMOStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMSStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNHStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNJStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNMStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNEStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNYStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldOHStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldOKStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldORStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldPAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldPRStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldRIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldSCStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldTNStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldUTStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldVAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWVStatesWhereCopyOfReturnIsFldCd
Own WebsiteYes (X)OwnWebsiteInd
Upon RequestYes (X)UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

FieldValueIRS element (for citing)
PersonROSEMARIE LOFFREDOPersonNm
Phone9149495213PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line11311 MAMARONECK AVENUEAddressLine1Txt
CityWHITE PLAINSCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10605ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (41 entries)

TitleTitleTxtAverage Hours Per WeekAverageHoursPerWeekRtAverage Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRtOfficerOfficerIndReportable Comp From OrgReportableCompFromOrgAmtReportable Comp From Rltd OrgReportableCompFromRltdOrgAmtOther CompensationOtherCompensationAmtKey EmployeeKeyEmployeeIndHighest Compensated EmployeeHighestCompensatedEmployeeIndFormer Ofcr Director TrusteeFormerOfcrDirectorTrusteeIndIndividual Trustee Or DirectorIndividualTrusteeOrDirectorInd
LOUIS J DEGENNARO
PRESIDENT &40.001.00Yes (X)$457,834$0$112,974
ROSEMARIE A LOFFREDO
EVP-CAO & CF40.001.00Yes (X)$312,192$0$24,816
GORDON MILLER JR
SVP FINANCE40.001.00Yes (X)$220,116$0$47,340
MARK ROITHMAYR
EVP-CHIEF DE40.00$353,760$0$50,033Yes (X)
GEORGE J OMIROS-TERM APR15
EVP-CHIEF CA40.00$318,316$0$50,125Yes (X)
BRIAN ROSEN - TERM FEB15
CHIEF POLICY40.00$292,610$0$29,649Yes (X)
LEE M GREENBERGER
SVP & CHIEF40.00$284,166$0$42,905Yes (X)
JEFFREY COMO-TERM DEC14
CHIEF INFORM40.00$438,470$0$21,907Yes (X)
LISA STOCKMON - TERM SEPT14
EVP-CHIEF MA40.00$278,930$0$21,359Yes (X)
GABRIELLE URQUHART-TERM JUN15
REGIONAL VP40.00$237,376$0$19,947Yes (X)
JOHN E WALTER - TERM FEB14
FORMER PRES40.001.00$839,890$0$24,354Yes (X)
JAMES H DAVIS PHD
CHAIR6.002.00Yes (X)$0$0$0Yes (X)
ELIZABETH J CLARK
VICE CHAIR4.002.00Yes (X)$0$0$0Yes (X)
KENNETH M SCHWARTZ
SECRETARY/TR4.002.00Yes (X)$0$0$0Yes (X)
DONALD PROCTOR
AT-LARGE4.002.00Yes (X)$0$0$0Yes (X)
JAMES A BECK
BOD MEMBER4.00$0$0$0Yes (X)
WILLIAM G BEHNKE
BOD MEMBER4.00$0$0$0Yes (X)
JORGE L BENITEZ
BOD MEMBER4.00$0$0$0Yes (X)
JAMES E BRADNER
BOD MEMBER4.00$0$0$0Yes (X)
PETER B BROCK
BOD MEMBER4.00$0$0$0Yes (X)
DANA A CALLOW JR
BOD MEMBER4.00$0$0$0Yes (X)
SCOTT A CARROLL
BOD MEMBER4.00$0$0$0Yes (X)
WILLIAM S DALTON
BOD MEMBER4.00$0$0$0Yes (X)
TIMOTHY DURST
BOD MEMBER4.00$0$0$0Yes (X)
GRACIELA C ELETA
BOD MEMBER4.00$0$0$0Yes (X)
BERNARD H GARIL
BOD MEMBER4.00$0$0$0Yes (X)
BETH E HAWLEY
BOD MEMBER4.00$0$0$0Yes (X)
FRANCIE HELLER
BOD MEMBER4.00$0$0$0Yes (X)
RAANAN HOROWITZ
BOD MEMBER4.00$0$0$0Yes (X)
RICHARD M JEANNERET
BOD MEMBER4.00$0$0$0Yes (X)
JOSEPH B KELLEY
BOD MEMBER4.00$0$0$0Yes (X)
RALPH LAWSON
BOD MEMBER4.00$0$0$0Yes (X)
MICHELLE LE BEAU
BOD MEMBER4.00$0$0$0Yes (X)
GILLES LEGAULT
BOD MEMBER4.00$0$0$0Yes (X)
CONNIE LINDSEY
BOD MEMBER4.00$0$0$0Yes (X)
STEVEN T ROSEN
BOD MEMBER4.00$0$0$0Yes (X)
FRANK O SMITH
BOD MEMBER4.00$0$0$0Yes (X)
KATHRYN C VECELLIO
BOD MEMBER4.00$0$0$0Yes (X)
LOUISE G WARNER
BOD MEMBER4.00$0$0$0Yes (X)
KEITH S WHITE
BOD MEMBER4.00$0$0$0Yes (X)
RODMAN N MYERS
LIFE MEMBER-1.00$0$0$0Yes (X)
FieldValueIRS element (for citing)
Total Reportable Comp From Org$4,033,660TotalReportableCompFromOrgAmt
Total Other Compensation$445,409TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K164IndivRcvdGreaterThan100KCnt
Former Ofcr Employees ListedYes (true)FormerOfcrEmployeesListedInd
Total Comp Greater Than150 KYes (true)TotalCompGreaterThan150KInd
Compensation From Other SrcsfalseCompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1TxtCityContractorAddress/USAddress/CityNmState AbbreviationContractorAddress/USAddress/StateAbbreviationCdZIPContractorAddress/USAddress/ZIPCdServicesServicesDescCompensationCompensationAmt
OLIVER STAFFING INC
350 LEXINGTON AV SUITE 401NEW YORKNY10016TEMP STAFFING$5,843,380
MAIL AMERICA COMMUNICATIONS
174 ELKTON FARM RDFORESTVA24551FUNDRAISING SER$4,304,214
PATIENT ADVOCACY FOUNDATION
421 BUTLER FARM RDHAMPTONVA23666PAT ASSIST PROC$4,176,617
RESOLUTE MEDIA LLC
137 W 25TH STNEW YORKNY10001DIGITAL MARKETI$2,100,611
COMPETITOR GROUP
9477 WAPLES STREETSAN DIEGOCA92121ENDURANCE SPORT$1,418,995
FieldValueIRS element (for citing)
Cntrct Rcvd Greater Than100 K84CntrctRcvdGreaterThan100KCnt
Federated Campaigns$1,859,098FederatedCampaignsAmt
Fundraising$162,196,401FundraisingAmt
All Other Contributions$119,854,485AllOtherContributionsAmt
Noncash Contributions$969,388NoncashContributionsAmt
Total Contributions$283,909,984TotalContributionsAmt

Investment Income InvestmentIncomeGrp

FieldValueIRS element (for citing)
Total Revenue Column$1,877,457TotalRevenueColumnAmt
Exclusion$1,877,457ExclusionAmt

Royalties Revenue RoyaltiesRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$13,955TotalRevenueColumnAmt
Exclusion$13,955ExclusionAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

FieldValueIRS element (for citing)
Securities$85,663,036SecuritiesAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

FieldValueIRS element (for citing)
Securities$82,627,172SecuritiesAmt

Gain Or Loss GainOrLossGrp

FieldValueIRS element (for citing)
Securities$3,035,864SecuritiesAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

FieldValueIRS element (for citing)
Total Revenue Column$3,035,864TotalRevenueColumnAmt
Exclusion$3,035,864ExclusionAmt
FieldValueIRS element (for citing)
Fundraising Gross Income$15,797,770FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event$162,196,401ContriRptFundraisingEventAmt
Fundraising Direct Expenses$23,557,444FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

FieldValueIRS element (for citing)
Total Revenue Column-$7,759,674TotalRevenueColumnAmt
Exclusion-$7,759,674ExclusionAmt
FieldValueIRS element (for citing)
Gaming Gross Income$631,918GamingGrossIncomeAmt
Gaming Direct Expenses$137,403GamingDirectExpensesAmt

Net Income From Gaming NetIncomeFromGamingGrp

FieldValueIRS element (for citing)
Total Revenue Column$494,515TotalRevenueColumnAmt
Exclusion$494,515ExclusionAmt

Other Revenue Misc OtherRevenueMiscGrp

FieldValueIRS element (for citing)
DescOTHER MISCELLANEOUSDesc
Business900099BusinessCd
Total Revenue Column$56,829TotalRevenueColumnAmt
Exclusion$56,829ExclusionAmt
FieldValueIRS element (for citing)
Other Revenue Total$56,829OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$281,628,930TotalRevenueColumnAmt
Exclusion-$2,281,054ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

FieldValueIRS element (for citing)
Total$58,051,232TotalAmt
Program Services$58,051,232ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

FieldValueIRS element (for citing)
Total$42,235,261TotalAmt
Program Services$42,235,261ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

FieldValueIRS element (for citing)
Total$7,709,561TotalAmt
Program Services$7,709,561ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

FieldValueIRS element (for citing)
Total$1,904,623TotalAmt
Program Services$1,250,249ProgramServicesAmt
Management And General$321,172ManagementAndGeneralAmt
Fundraising$333,202FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

FieldValueIRS element (for citing)
Total$68,051,957TotalAmt
Program Services$44,648,621ProgramServicesAmt
Management And General$11,495,171ManagementAndGeneralAmt
Fundraising$11,908,165FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

FieldValueIRS element (for citing)
Total$1,663,579TotalAmt
Program Services$944,099ProgramServicesAmt
Management And General$409,403ManagementAndGeneralAmt
Fundraising$310,077FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

FieldValueIRS element (for citing)
Total$9,358,662TotalAmt
Program Services$5,311,142ProgramServicesAmt
Management And General$2,303,141ManagementAndGeneralAmt
Fundraising$1,744,379FundraisingAmt

Payroll Taxes PayrollTaxesGrp

FieldValueIRS element (for citing)
Total$4,700,672TotalAmt
Program Services$2,667,682ProgramServicesAmt
Management And General$1,156,823ManagementAndGeneralAmt
Fundraising$876,167FundraisingAmt

Fees For Services Legal FeesForServicesLegalGrp

FieldValueIRS element (for citing)
Total$784,221TotalAmt
Program Services$491,513ProgramServicesAmt
Management And General$128,390ManagementAndGeneralAmt
Fundraising$164,318FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

FieldValueIRS element (for citing)
Total$292,025TotalAmt
Program Services$183,027ProgramServicesAmt
Management And General$47,810ManagementAndGeneralAmt
Fundraising$61,188FundraisingAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

FieldValueIRS element (for citing)
Total$623,467TotalAmt
Program Services$390,759ProgramServicesAmt
Management And General$102,073ManagementAndGeneralAmt
Fundraising$130,635FundraisingAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

FieldValueIRS element (for citing)
Total$4,709,809TotalAmt
Fundraising$4,709,809FundraisingAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

FieldValueIRS element (for citing)
Total$75,197TotalAmt
Program Services$47,131ProgramServicesAmt
Management And General$12,311ManagementAndGeneralAmt
Fundraising$15,755FundraisingAmt

Fees For Services Other FeesForServicesOtherGrp

FieldValueIRS element (for citing)
Total$18,219,202TotalAmt
Program Services$11,418,920ProgramServicesAmt
Management And General$2,982,803ManagementAndGeneralAmt
Fundraising$3,817,479FundraisingAmt

Advertising AdvertisingGrp

FieldValueIRS element (for citing)
Total$7,475,264TotalAmt
Program Services$3,318,576ProgramServicesAmt
Management And General$1,018,944ManagementAndGeneralAmt
Fundraising$3,137,744FundraisingAmt

Office Expenses OfficeExpensesGrp

FieldValueIRS element (for citing)
Total$20,158,375TotalAmt
Program Services$8,691,467ProgramServicesAmt
Management And General$2,271,929ManagementAndGeneralAmt
Fundraising$9,194,979FundraisingAmt

Information Technology InformationTechnologyGrp

FieldValueIRS element (for citing)
Total$6,188,376TotalAmt
Program Services$3,878,576ProgramServicesAmt
Management And General$1,013,146ManagementAndGeneralAmt
Fundraising$1,296,654FundraisingAmt

Occupancy OccupancyGrp

FieldValueIRS element (for citing)
Total$9,023,616TotalAmt
Program Services$5,601,465ProgramServicesAmt
Management And General$1,754,904ManagementAndGeneralAmt
Fundraising$1,667,247FundraisingAmt

Travel TravelGrp

FieldValueIRS element (for citing)
Total$5,121,398TotalAmt
Program Services$3,449,430ProgramServicesAmt
Management And General$737,063ManagementAndGeneralAmt
Fundraising$934,905FundraisingAmt

Conferences Meetings ConferencesMeetingsGrp

FieldValueIRS element (for citing)
Total$2,462,185TotalAmt
Program Services$1,981,473ProgramServicesAmt
Management And General$263,068ManagementAndGeneralAmt
Fundraising$217,644FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

FieldValueIRS element (for citing)
Total$5,721,945TotalAmt
Program Services$2,068,849ProgramServicesAmt
Management And General$2,473,456ManagementAndGeneralAmt
Fundraising$1,179,640FundraisingAmt

Insurance InsuranceGrp

FieldValueIRS element (for citing)
Total$594,312TotalAmt
Program Services$247,009ProgramServicesAmt
Management And General$236,700ManagementAndGeneralAmt
Fundraising$110,603FundraisingAmt

Other Expenses OtherExpensesGrp (2 entries)

DescDescTotalTotalAmtProgram ServicesProgramServicesAmtManagement And GeneralManagementAndGeneralAmtFundraisingFundraisingAmt
MISCELLANEOUS$2,027,268$1,079,451$466,829$480,988
DUES & SUBSCRIPTIONS$290,850$129,120$39,645$122,085

Total Functional Expenses TotalFunctionalExpensesGrp

FieldValueIRS element (for citing)
Total$277,443,057TotalAmt
Program Services$205,794,613ProgramServicesAmt
Management And General$29,234,781ManagementAndGeneralAmt
Fundraising$42,413,663FundraisingAmt
FieldValueIRS element (for citing)
Joint CostsYes (X)JointCostsInd

Total Joint Costs TotalJointCostsGrp

FieldValueIRS element (for citing)
Total$12,521,693TotalAmt
Program Services$2,812,241ProgramServicesAmt
Fundraising$9,709,452FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

FieldValueIRS element (for citing)
BOY$6,268,949BOYAmt
EOY$7,141,619EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

FieldValueIRS element (for citing)
BOY$20,220,498BOYAmt
EOY$42,601,449EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

FieldValueIRS element (for citing)
BOY$8,575,572BOYAmt
EOY$8,633,988EOYAmt

Accounts Receivable AccountsReceivableGrp

FieldValueIRS element (for citing)
BOY$311BOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

FieldValueIRS element (for citing)
BOY$4,955,078BOYAmt
EOY$5,813,918EOYAmt
FieldValueIRS element (for citing)
Land Bldg Equip Cost Or Other Bss$35,132,960LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec$20,430,449LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

FieldValueIRS element (for citing)
BOY$16,409,608BOYAmt
EOY$14,702,511EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

FieldValueIRS element (for citing)
BOY$128,829,280BOYAmt
EOY$86,639,070EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

FieldValueIRS element (for citing)
BOY$57,322,231BOYAmt
EOY$48,953,251EOYAmt

Total Assets TotalAssetsGrp

FieldValueIRS element (for citing)
BOY$242,581,527BOYAmt
EOY$214,485,806EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

FieldValueIRS element (for citing)
BOY$20,275,231BOYAmt
EOY$17,799,196EOYAmt

Grants Payable GrantsPayableGrp

FieldValueIRS element (for citing)
BOY$99,130,986BOYAmt
EOY$81,859,872EOYAmt

Deferred Revenue DeferredRevenueGrp

FieldValueIRS element (for citing)
BOY$26,038,202BOYAmt
EOY$17,304,792EOYAmt

Total Liabilities TotalLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$145,444,419BOYAmt
EOY$116,963,860EOYAmt
FieldValueIRS element (for citing)
Organization Follows SFAS117Yes (X)OrganizationFollowsSFAS117Ind

Unrestricted Net Assets UnrestrictedNetAssetsGrp

FieldValueIRS element (for citing)
BOY$67,582,758BOYAmt
EOY$71,640,456EOYAmt

Temporarily Rstr Net Assets TemporarilyRstrNetAssetsGrp

FieldValueIRS element (for citing)
BOY$26,592,408BOYAmt
EOY$22,847,577EOYAmt

Permanently Rstr Net Assets PermanentlyRstrNetAssetsGrp

FieldValueIRS element (for citing)
BOY$2,961,942BOYAmt
EOY$3,033,913EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$97,137,108BOYAmt
EOY$97,521,946EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$242,581,527BOYAmt
EOY$214,485,806EOYAmt
FieldValueIRS element (for citing)
Info In Schedule O Part XIYes (X)InfoInScheduleOPartXIInd
Reconcilation Revenue Expnss$4,185,873ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst-$3,934,019NetUnrlzdGainsLossesInvstAmt
Other Changes In Net Assets$132,984OtherChangesInNetAssetsAmt
Method Of Accounting AccrualYes (X)MethodOfAccountingAccrualInd
Accountant Compile Or ReviewYes (true)AccountantCompileOrReviewInd
FS AuditedYes (true)FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

FieldValueIRS element (for citing)
Consolidated Basis Fincl StmtYes (X)ConsolidatedBasisFinclStmtInd
FieldValueIRS element (for citing)
Audit CommitteeYes (true)AuditCommitteeInd
Federal Grant Audit RequiredfalseFederalGrantAuditRequiredInd

Schedule A IRS990ScheduleA

FieldValueIRS element (for citing)
Public Organization170Yes (X)PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$270,043,865CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$282,672,072CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$279,789,664CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$302,437,152CurrentTaxYearMinus1YearAmt
Current Tax Year$283,909,984CurrentTaxYearAmt
Total$1,418,852,737TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$270,043,865CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$282,672,072CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$279,789,664CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$302,437,152CurrentTaxYearMinus1YearAmt
Current Tax Year$283,909,984CurrentTaxYearAmt
Total$1,418,852,737TotalAmt
FieldValueIRS element (for citing)
Substantial Contributors Tot$222,588,669SubstantialContributorsTotAmt
Public Support Total170$1,196,264,068PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$3,145,637CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$2,705,046CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$2,260,636CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$1,203,865CurrentTaxYearMinus1YearAmt
Current Tax Year$1,891,412CurrentTaxYearAmt
Total$11,206,596TotalAmt

Other Income170 OtherIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$1,779,485CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$1,502,044CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$1,974,227CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$104,879CurrentTaxYearMinus1YearAmt
Current Tax Year$56,829CurrentTaxYearAmt
Total$5,417,464TotalAmt
FieldValueIRS element (for citing)
Total Support$1,435,476,797TotalSupportAmt
Gross Receipts Rltd Activities$160,341,605GrossReceiptsRltdActivitiesAmt
Public Support CY1700.83340PublicSupportCY170Pct
Public Support PY1700.84500PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170Yes (X)ThirtyThrPctSuprtTestsCY170Ind

Form990 Schedule A Part VI Form990ScheduleAPartVIGrp

FieldValueIRS element (for citing)
Form And Line ReferencePART II, LINE 10FormAndLineReferenceDesc
ExplanationGRANT TERMINATIONS & REFUNDS 5,069,350 OTHER MISC. REVENUE 348,114ExplanationTxt

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

FieldValueIRS element (for citing)
ContributorRESTRICTEDContributorNum

Contributor Business Name ContributorBusinessName

FieldValueIRS element (for citing)
Business Name Line1RESTRICTEDBusinessNameLine1

Contributor US Address ContributorUSAddress

FieldValueIRS element (for citing)
Address Line1RESTRICTEDAddressLine1
Address Line2RESTRICTEDAddressLine2
CityRESTRICTEDCity
StateRESTRICTEDState
ZIP CodeRESTRICTEDZIPCode
FieldValueIRS element (for citing)
Total ContributionsRESTRICTEDTotalContributionsAmt

Schedule C IRS990ScheduleC

FieldValueIRS element (for citing)
VolunteersYes (true)VolunteersInd
Paid Staff Or ManagementYes (true)PaidStaffOrManagementInd
Media AdvertisementsfalseMediaAdvertisementsInd
Mailings MembersfalseMailingsMembersInd
Publications Or BroadcastYes (true)PublicationsOrBroadcastInd
Publications Or Broadcast$149,762PublicationsOrBroadcastAmt
Grants Other OrganizationsfalseGrantsOtherOrganizationsInd
Direct Contact LegislatorsYes (true)DirectContactLegislatorsInd
Direct Contact Legislators$164,749DirectContactLegislatorsAmt
Rallies DemonstrationsYes (true)RalliesDemonstrationsInd
Rallies Demonstrations$236,088RalliesDemonstrationsAmt
Other ActivitiesYes (true)OtherActivitiesInd
Other Activities$623,467OtherActivitiesAmt
Total Lobbying Expenditures$1,174,066TotalLobbyingExpendituresAmt
Not Described Section501c3falseNotDescribedSection501c3Ind

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE C, PART II-B, LINE 1FormAndLineReferenceDesc
ExplanationLLS IS A MEMBER OF A NUMBER OF COALITIONS AND MEMBERSHIPS INCLUDING FRIENDS OF CANCER RESEARCH, ALLIANCE FOR A STRONGER FDA, ONE VOICE AGAINST CANCER, NATIONAL HEALTH COUNCIL, THE CANCER LEADERSHIP COUNCIL AND THE STATE ACCESS TO INNOVATIVE MEDICINES COALITION. LLS PARTNERS WITH A NUMBER OF LOBBYING FIRMS WHO WORK WITH OUR PUBLIC POLICY STAFF TO CARRY OUT OUR LOBBYING OBJECTIVES. LLS MOBILIZES PATIENT-ADVOCATES AND VOLUNTEERS TO ENGAGE WITH THEIR FEDERAL AND STATE LEGISLATORS THROUGH DIGITAL ADVOCACY - SENDING LETTERS; SHARING THEIR PERSONAL STORIES; SIGNING PETITIONS; AND ENCOURAGING THEIR LEGISLATORS TO SUPPORT LLS' POLICY PRIORITIES. IN CONJUNCTION WITH LLS EMPLOYEES, PATIENT-ADVOCATES ALSO VISIT THEIR LEGISLATORS IN THEIR LOCAL OFFICES, IN WASHINGTON, DC AND IN STATE CAPITOLS TO FURTHER LLS' POLICY AGENDA.ExplanationTxt

Schedule D IRS990ScheduleD

FieldValueIRS element (for citing)
Collection Used Pub ExhibitionYes (X)CollectionUsedPubExhibitionInd
Solicited Assets SalefalseSolicitedAssetsSaleInd

CY Endwmt Fund CYEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$6,122,698BeginningYearBalanceAmt
Investment Earnings Or Losses$218,549InvestmentEarningsOrLossesAmt
Grants Or Scholarships-$221,499GrantsOrScholarshipsAmt
Administrative Expenses-$4,103AdministrativeExpensesAmt
End Year Balance$6,115,645EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$6,027,657BeginningYearBalanceAmt
Investment Earnings Or Losses$313,872InvestmentEarningsOrLossesAmt
Grants Or Scholarships-$215,000GrantsOrScholarshipsAmt
Administrative Expenses-$3,831AdministrativeExpensesAmt
End Year Balance$6,122,698EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$6,000,186BeginningYearBalanceAmt
Investment Earnings Or Losses$482,520InvestmentEarningsOrLossesAmt
Grants Or Scholarships-$450,000GrantsOrScholarshipsAmt
Administrative Expenses-$5,049AdministrativeExpensesAmt
End Year Balance$6,027,657EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$6,059,994BeginningYearBalanceAmt
Investment Earnings Or Losses$48,916InvestmentEarningsOrLossesAmt
Administrative Expenses-$9,992AdministrativeExpensesAmt
End Year Balance$6,000,186EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$5,023,902BeginningYearBalanceAmt
Contributions$111,064ContributionsAmt
Investment Earnings Or Losses$938,068InvestmentEarningsOrLossesAmt
Administrative Expenses-$13,040AdministrativeExpensesAmt
End Year Balance$6,059,994EndYearBalanceAmt
FieldValueIRS element (for citing)
Prmnnt Endowment Balance EOY0.50000PrmnntEndowmentBalanceEOYPct
Term Endowment Balance EOY0.50000TermEndowmentBalanceEOYPct
Endowments Held Unrelated OrgfalseEndowmentsHeldUnrelatedOrgInd
Endowments Held Related OrgfalseEndowmentsHeldRelatedOrgInd

Leasehold Improvements LeaseholdImprovementsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$942,329OtherCostOrOtherBasisAmt
Depreciation$504,716DepreciationAmt
Book Value$437,613BookValueAmt

Equipment EquipmentGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$31,500,031OtherCostOrOtherBasisAmt
Depreciation$17,235,878DepreciationAmt
Book Value$14,264,153BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$2,690,600OtherCostOrOtherBasisAmt
Depreciation$2,689,855DepreciationAmt
Book Value$745BookValueAmt
FieldValueIRS element (for citing)
Total Book Value Land Buildings$14,702,511TotalBookValueLandBuildingsAmt

Other Securities OtherSecuritiesGrp (3 entries)

DescDescBook ValueBookValueAmtMethod ValuationMethodValuationCd
FUND OF HEDGE FUNDS- OPERATING$46,036,786F
457B PLAN$1,491,954F
FUND OF HEDGE FUNDS-ENDOWMENT$1,424,511F
FieldValueIRS element (for citing)
Total Book Value Securities$48,953,251TotalBookValueSecuritiesAmt
Footnote TextYes (X)FootnoteTextInd
Total Rev Etc Audited Fincl Stmt$298,163,084TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst-$3,934,019NetUnrealizedGainsInvstAmt
Donated Services And Use Fclts$9,864,376DonatedServicesAndUseFcltsAmt
Other Revenue$10,678,994OtherRevenueAmt
Revenue Not Reported$16,609,351RevenueNotReportedAmt
Revenue Subtotal$281,553,733RevenueSubtotalAmt
Investment Expenses Not Incld$75,197InvestmentExpensesNotIncldAmt
Revenue Not Reported Fincl Stmt$75,197RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990$281,628,930TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt$297,885,296TotExpnsEtcAuditedFinclStmtAmt
Donated Services Use Fclts$9,864,376DonatedServicesUseFcltsAmt
Other Expenses Included$10,653,060OtherExpensesIncludedAmt
Expenses Not Reported$20,517,436ExpensesNotReportedAmt
Expenses Subtotal$277,367,860ExpensesSubtotalAmt
Investment Expenses Not Incld2$75,197InvestmentExpensesNotIncld2Amt
Expenses Not Rpt Fincl Stmt$75,197ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990$277,443,057TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (5 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
SCHEDULE D, PAGE 2, PART III, LINE 4THE LLS COLLECTION IS OF PHOTOGRAPHS WHICH ARE USED FOR PUBLIC EXHIBITION AT FUNDRAISING EVENTS HELD TO SUPPORT LLS'S PROGRAMS.
SCHEDULE D, PAGE 2, PART V, LINE 4LLS'S ENDOWMENTS ARE INTENDED TO FUND RESEARCH AS WELL AS SUPPORT LLS'S PUBLIC EDUCATION PROGRAMS.
SCHEDULE D, PAGE 3, PART XLLS RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE TAX POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO LLS'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENUE CODE SECTION 511. LLS DID NOT RECOGNIZE ANY UNRELATED BUSINESS INCOME TAX LIABILITY FOR THE YEARS ENDED JUNE 30, 2015 AND 2014.
SCHEDULE D, PAGE 4, PART XI, LINE 2DLLS CANADA REVENUE 10,501,177 LLS CANADA GAIN ON INVESTMENT 177,817
SCHEDULE D, PAGE 4, PART XII, LINE 2DLLS CANADA EXPENSES 10,122,744 FOREIGN CURRENCY TRANSLATION 530,316

Schedule F IRS990ScheduleF

FieldValueIRS element (for citing)
Grant Records MaintainedYes (true)GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (4 entries)

RegionRegionTxtEmployeeEmployeeCntType Of Activities ConductedTypeOfActivitiesConductedTxtSpecific Services ProvidedSpecificServicesProvidedTxtRegion Total ExpendituresRegionTotalExpendituresAmtOfficesOfficesCnt
EAST ASIA3RESEARCH FUNDINGRESEARCH GRANTS$1,695,000
EUROPE13RESEARCH FUNDINGRESEARCH GRANTS$4,351,803
NORTH AMERICA6RESEARCH FUNDINGRESEARCH GRANTS$1,662,7587
CENTRAL AMERICA & CARIBBEANINVESTMENTSINVESTMENTS$20,635,431
FieldValueIRS element (for citing)
Subtotal Offices7SubtotalOfficesCnt
Subtotal Employees22SubtotalEmployeesCnt
Total Office7TotalOfficeCnt
Total Employee22TotalEmployeeCnt
Subtotal Spent$28,344,992SubtotalSpentAmt
Total Spent$28,344,992TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (22 entries)

RegionRegionTxtPurpose Of GrantPurposeOfGrantTxtCash GrantCashGrantAmtManner Of Cash DisbursementMannerOfCashDisbursementTxtValuation Method UsedValuationMethodUsedDesc
EAST ASIA & PACIFICRESEARCH GRANT$1,250,000CHECKACCRUAL
EAST ASIA & PACIFICRESEARCH GRANT$55,000CHECKACCRUAL
EAST ASIA & PACIFICRESEARCH GRANT$390,000CHECKACCRUAL
EUROPERESEARCH GRANT$65,000CHECKACCRUAL
EUROPERESEARCH GRANT$200,000CHECKACCRUAL
EUROPERESEARCH GRANT$55,000CHECKACCRUAL
EUROPERESEARCH GRANT$1,250,000CHECKACCRUAL
EUROPERESEARCH GRANT$110,000CHECKACCRUAL
EUROPERESEARCH GRANT$200,000CHECKACCRUAL
EUROPERESEARCH GRANT$200,000CHECKACCRUAL
EUROPERESEARCH GRANT$395,665CHECKACCRUAL
EUROPETHERAPY ACCELERATION$1,000,000WIREFMV
EUROPETHERAPY ACCELERATION$750,000WIREFMV
EUROPETHERAPY ACCELERATION$16,138CHECKFMV
EUROPETHERAPY ACCELERATION$10,000CHECKFMV
EUROPETHERAPY ACCELERATION$100,000CHECKFMV
NORTH AMERICARESEARCH GRANT$200,000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT$200,000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT$300,000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT$200,000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT$363,353CHECKACCRUAL
NORTH AMERICARESEARCH GRANT$399,405CHECKACCRUAL
FieldValueIRS element (for citing)
Total Other Org18TotalOtherOrgCnt
Transfer To Foreign CorpYes (true)TransferToForeignCorpInd
Interest In Foreign TrustfalseInterestInForeignTrustInd
Foreign Corp OwnershipYes (true)ForeignCorpOwnershipInd
Passive Foreign Investmest CoYes (true)PassiveForeignInvestmestCoInd
Foreign PartnershipfalseForeignPartnershipInd
Boycott CountriesfalseBoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
SCHEDULE F, PAGE 1, PART I, LINE 2FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT.
SCHEDULE F, PAGE 1, PART I, LINE 3EAST ASIA 1,695,000 0 EUROPE 4,351,803 0 NORTH AMERICA 1,662,758 0 CENTRAL AMERICA & CARIBBEAN 0 20,635,431

Schedule G IRS990ScheduleG

FieldValueIRS element (for citing)
Mail SolicitationsYes (X)MailSolicitationsInd
Email SolicitationsYes (X)EmailSolicitationsInd
Phone SolicitationsYes (X)PhoneSolicitationsInd
In Person SolicitationsYes (X)InPersonSolicitationsInd
Solicitation Of Non Govt GrantsYes (X)SolicitationOfNonGovtGrantsInd
Special Fundraising EventsYes (X)SpecialFundraisingEventsInd
Agrmt Prof Fundraising ActyYes (true)AgrmtProfFundraisingActyInd

Fundraiser Activity Info FundraiserActivityInfoGrp (5 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdActivityActivityTxtFundraiser Control Of FundsFundraiserControlOfFundsIndRetained By ContractorRetainedByContractorAmtNet To OrganizationNetToOrganizationAmt
MAIL AMERICA COMMUNICATIONS INC
174 ELKTON FARM ROADFORESTVA24551DIRECT MAIfalse$5,000,715-$5,000,715
INFOCISION MANAGEMENT CORPORATION
325 SPRINSIDE DRIVEAKRONOH44333TELEMARKETfalse$828,717-$828,717
THOMPSON HABIB & DENISON
80 HAYDEN AVENUE SUITE 300LEXINGTONMA02421DIRECT MAIfalse$575,275-$575,275
COINSTAR
1800 114TH AVENUE SEBELLEVUEWA98004COIN COLLEfalse$400,303-$400,303
DONOR CARE CENTER INC
4345 STRAUSSSER ST NWNORTH CANTONOH44720TELEMARKETfalse$212,080-$212,080
FieldValueIRS element (for citing)
Total Retained By Contractors$7,017,090TotalRetainedByContractorsAmt
Total Net To Organization-$7,017,090TotalNetToOrganizationAmt
All StatesAll StatesAllStatesCd

Fundraising Event Information FundraisingEventInformationGrp

FieldValueIRS element (for citing)
Event1NIKE WOMEN MARAEvent1Nm
Gross Receipts Event1$4,507,326GrossReceiptsEvent1Amt
Charitable Contri Event1$4,476,491CharitableContriEvent1Amt
Gross Revenue Event1$30,835GrossRevenueEvent1Amt
Non Cash Prizes Event1$8,829NonCashPrizesEvent1Amt
Rent Facility Costs Event1$556,046RentFacilityCostsEvent1Amt
Food And Beverage Event1$77,427FoodAndBeverageEvent1Amt
Other Direct Expenses Event1$547,023OtherDirectExpensesEvent1Amt
Event2LAKE TAHOE CYCLEvent2Nm
Gross Receipts Event2$3,308,624GrossReceiptsEvent2Amt
Charitable Contri Event2$3,294,124CharitableContriEvent2Amt
Gross Revenue Event2$14,500GrossRevenueEvent2Amt
Non Cash Prizes Event2$63,659NonCashPrizesEvent2Amt
Rent Facility Costs Event2$190,171RentFacilityCostsEvent2Amt
Food And Beverage Event2$31,311FoodAndBeverageEvent2Amt
Other Direct Expenses Event2$261,890OtherDirectExpensesEvent2Amt
Other Events Total741OtherEventsTotalCnt
Gross Receipts Other Events$170,178,221GrossReceiptsOtherEventsAmt
Charitable Contri Other Events$154,425,786CharitableContriOtherEventsAmt
Gross Revenue Other Events$15,752,435GrossRevenueOtherEventsAmt
Non Cash Prizes Other Events$3,806,128NonCashPrizesOtherEventsAmt
Rent Fclty Costs Other Events$7,237,129RentFcltyCostsOtherEventsAmt
Food And Beverage Other Events$3,240,623FoodAndBeverageOtherEventsAmt
Entertainment Other Events$1,083,633EntertainmentOtherEventsAmt
Oth Direct Expnss Other Events$6,453,575OthDirectExpnssOtherEventsAmt
Gross Receipts Total$177,994,171GrossReceiptsTotalAmt
Charitable Contributions Tot$162,196,401CharitableContributionsTotAmt
Gross Revenue Total Events$15,797,770GrossRevenueTotalEventsAmt
Non Cash Prizes Total Events$3,878,616NonCashPrizesTotalEventsAmt
Rent Fclty Costs Total Events$7,983,346RentFcltyCostsTotalEventsAmt
Food And Beverage Total Events$3,349,361FoodAndBeverageTotalEventsAmt
Entertainment Total Events$1,083,633EntertainmentTotalEventsAmt
Oth Direct Expnss Total Events$7,262,488OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events$23,557,444DirectExpenseSummaryEventsAmt
Net Income Summary-$7,759,674NetIncomeSummaryAmt

Gaming Information GamingInformationGrp

FieldValueIRS element (for citing)
Volunteer Labor BingofalseVolunteerLaborBingoInd
Volunteer Labor Pull TabsfalseVolunteerLaborPullTabsInd
Gross Revenue Other Gaming$631,918GrossRevenueOtherGamingAmt
Cash Prizes Other Gaming$3,913CashPrizesOtherGamingAmt
Non Cash Prizes Other Gaming$129,490NonCashPrizesOtherGamingAmt
Oth Direct Expnss Other Gaming$4,000OthDirectExpnssOtherGamingAmt
Volunteer Labor Other GamingYes (true)VolunteerLaborOtherGamingInd
Volunteer Labor Other Gaming0.90000VolunteerLaborOtherGamingPct
Gross Revenue Total Gaming$631,918GrossRevenueTotalGamingAmt
Cash Prizes Total Gaming$3,913CashPrizesTotalGamingAmt
Non Cash Prizes Total Gaming$129,490NonCashPrizesTotalGamingAmt
Oth Direct Expnss Total Gaming$4,000OthDirectExpnssTotalGamingAmt
Direct Expense Summary Gaming$137,403DirectExpenseSummaryGamingAmt
Net Gaming Income Summary$494,515NetGamingIncomeSummaryAmt
FieldValueIRS element (for citing)
LicensedYes (true)LicensedInd
License Suspended EtcfalseLicenseSuspendedEtcInd
Gaming With NonmembersfalseGamingWithNonmembersInd
Member Of Other EntityfalseMemberOfOtherEntityInd
Gaming Own Facility0.25000GamingOwnFacilityPct
Gaming Other Facility0.75000GamingOtherFacilityPct
Individual With BooksROSEMARIE LOFFREDOIndividualWithBooksNm

Persons With Books US Address PersonsWithBooksUSAddress

FieldValueIRS element (for citing)
Address Line11311 MAMARONECK AVENUEAddressLine1Txt
CityWHITE PLAINSCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10605ZIPCd
FieldValueIRS element (for citing)
Cntrct With3rd Prty For Game RevfalseCntrctWith3rdPrtyForGameRevInd
Gaming Manager PersonSEE SCHEDULE G PART IVGamingManagerPersonNm
Charitable Distribution RqrfalseCharitableDistributionRqrInd

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE G, PART IVFormAndLineReferenceDesc
ExplanationSCHEDULE G PART I, LINE 2B LLS USED MAIL AMERICA COMMUNICATIONS AND THOMPSON, HABIB & DENISON FOR ITS NATIONAL COMMUNITY CAMPAIGN AND DIRECT MAIL PROGRAMS. THESE PROGRAMS GENERATED GROSS RECEIPTS OF 20,336,576 DURING FISCAL YEAR 2015. LLS USED INFOCISION MANAGEMENT CORPORATION, COINSTAR AND DONOR CARE CENTER FOR ALL OF ITS OTHER FUNDRAISING EVENTS DURING FISCAL YEAR 2015. SCHEDULE G, PART II - LINE 2 CONTRIBUTIONS REPRESENT THE CASH DONATIONS IN EXCESS OF THE FAIR MARKET VALUE OF BENEFITS PROVIDED TO THE DONOR. SCHEDULE G, PART II, LINES 4 - 10 DIRECT EXPENSES ARE COSTS INCURRED BY THE ORGANIZATION TO HOST THE EVENTS. SCHEDULE G, PART III, LINE 9 - STATES WITH GAMING OPERATIONS ARIZONA, DISTRICT OF COLUMBIA, IOWA, KANSAS, LOUISIANA, MICHIGAN, NEVADA, NEW YORK, OHIO, OREGON, PENNSYLVANIA, RHODE ISLAND, TEXAS, WISCONSIN. SCHEDULE G, PART III, LINE 16 THE LEUKEMIA & LYMPHOMA SOCIETY DOES NOT HAVE AN OVERALL MANAGER FOR GAMING ACTIVITIES. EACH GAMING EVENT IS MANAGED LOCALLY BY THE SPECIFIC CHAPTER STAFF.ExplanationTxt

Schedule I IRS990ScheduleI

FieldValueIRS element (for citing)
Grant Records MaintainedYes (true)GrantRecordsMaintainedInd

Recipient Table RecipientTable (282 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdRecipient EINRecipientEINIRC SectionIRCSectionDescCash GrantCashGrantAmtValuation Method UsedValuationMethodUsedDescPurpose Of GrantPurposeOfGrantTxt
ALBERT EINSTEIN COLLEGE OF MEDICINE
1300 MORRSIS PARK AVEBRONXNY104611316242253$200,000ACCRUALRESEARCH GRANT
ALBERT EINSTEIN COLLEGE OF MEDICINE
1300 MORRSIS PARK AVEBRONXNY104611316242253$110,000ACCRUALRESEARCH GRANT
ALBERT EINSTEIN COLLEGE OF MEDICINE
1300 MORRSIS PARK AVEBRONXNY104611316242253$200,000ACCRUALRESEARCH GRANT
ALBERT EINSTEIN COLLEGE OF MEDICINE
1300 MORRSIS PARK AVEBRONXNY104611316242253$200,000ACCRUALRESEARCH GRANT
ALBERT EINSTEIN COLLEGE OF MEDICINE
1300 MORRSIS PARK AVEBRONXNY104611316242253$110,000ACCRUALRESEARCH GRANT
ALBERT EINSTEIN COLLEGE OF MEDICINE
1300 MORRSIS PARK AVEBRONXNY104611316242253$200,000ACCRUALRESEARCH GRANT
BAYLOR COLLEGE OF MEDICINE
1 BAYLOR PLAZAHOUSTONTX770307416138783$200,000ACCRUALRESEARCH GRANT
BAYLOR COLLEGE OF MEDICINE
1 BAYLOR PLAZAHOUSTONTX770317416138783$200,000ACCRUALRESEARCH GRANT
BAYLOR COLLEGE OF MEDICINE
1 BAYLOR PLAZAHOUSTONTX770327416138783$1,250,000ACCRUALRESEARCH GRANT
BAYLOR COLLEGE OF MEDICINE
1 BAYLOR PLAZAHOUSTONTX770337416138783$200,000ACCRUALRESEARCH GRANT
BECKMAN RESEARCH INSTITUTE OF CITY
1500 DUARTE ROADDUARTECA9101030009534322103$400,000ACCRUALRESEARCH GRANT
BECKMAN RESEARCH INSTITUTE OF THE C
1500 DUARTE ROADDUARTECA910109534322103$200,000ACCRUALRESEARCH GRANT
BECKMAN RESEARCH INSTITUTE OF THE C
1500 DUARTE ROADDUARTECA910109534322103$200,000ACCRUALRESEARCH GRANT
BETH ISRAEL DEACONESS MEDICAL CENTE
330 BROOKLINE AVENUEBOSTONMA022150421038813$200,000ACCRUALRESEARCH GRANT
BETH ISRAEL DEACONESS MEDICAL CENTE
330 BROOKLINE AVENUEBOSTONMA022150421038813$55,000ACCRUALRESEARCH GRANT
BETH ISRAEL DEACONESS MEDICAL CENTE
330 BROOKLINE AVENUEBOSTONMA022150421038813$110,000ACCRUALRESEARCH GRANT
BRANDEIS UNIVERSITY
415 SOUTH STREETWALTHAMMA024530421035523$55,000ACCRUALRESEARCH GRANT
BRIGHAM & WOMENS HOSPITAL
75 FRANCIS STREETBOSTONMA021150423129093$1,250,000ACCRUALRESEARCH GRANT
BRIGHAM & WOMENS HOSPITAL
75 FRANCIS STREETBOSTONMA021150423129093$200,000ACCRUALRESEARCH GRANT
BRIGHAM & WOMENS HOSPITAL
75 FRANCIS STREETBOSTONMA021150423129093$110,000ACCRUALRESEARCH GRANT
BRIGHAM & WOMENS HOSPITAL
75 FRANCIS STREETBOSTONMA021150423129093$110,000ACCRUALRESEARCH GRANT
BRIGHAM & WOMENS HOSPITAL
75 FRANCIS STREETBOSTONMA021150423129093$55,000ACCRUALRESEARCH GRANT
CALIFORNIA INSTITUTE OF TECHNOLOGY
12200 E CALIFORNIA BLVDPASADENACA911259516433073$55,000ACCRUALRESEARCH GRANT
CALIFORNIA INSTITUTE OF TECHNOLOGY
12200 E CALIFORNIA BLVDPASADENACA911259516433073$55,000ACCRUALRESEARCH GRANT
CASE WESTERN RESERVE UNIVERSITY - S
2109 ADELBERT ROADCLEVELANDOH441063410189923$200,000ACCRUALRESEARCH GRANT
CASE WESTERN RESERVE UNIVERSITY - S
2109 ADELBERT ROADCLEVELANDOH441063410189923$200,000ACCRUALRESEARCH GRANT
CEDARS-SINAI MEDICAL CENTER
8700 BEVERLY BLVDLOS ANGELESCA900489516446003$133,333ACCRUALRESEARCH GRANT
CHILDRENS HOSPITAL CORPORATION
300 LONGWOOD AVENUEBOSTONMA021150427744413$65,000ACCRUALRESEARCH GRANT
CHILDRENS HOSPITAL CORPORATION
300 LONGWOOD AVENUEBOSTONMA021150427744413$55,000ACCRUALRESEARCH GRANT
CHILDRENS HOSPITAL CORPORATION
300 LONGWOOD AVENUEBOSTONMA021150427744413$55,000ACCRUALRESEARCH GRANT
CHILDRENS HOSPITAL CORPORATION
300 LONGWOOD AVENUEBOSTONMA021150427744413$55,000ACCRUALRESEARCH GRANT
CHILDREN'S HOSPITAL OF PHILADELPHIA
CIVIC CENTER BLVDPHILADELPHIAPA191042313521663$200,000ACCRUALRESEARCH GRANT
CHILDREN'S HOSPITAL OF PHILADELPHIA
CIVIC CENTER BLVDPHILADELPHIAPA191042313521663$110,000ACCRUALRESEARCH GRANT
CINCINNATI CHILDRENS HOSPITAL MEDI
3333 BURNET AVENUECINCINATTIOH452093108339363$110,000ACCRUALRESEARCH GRANT
CINCINNATI CHILDREN'S HOSPITAL MEDI
3333 BURNET AVENUECINCINATTIOH452093108339363$200,000ACCRUALRESEARCH GRANT
CINCINNATI CHILDREN'S HOSPITAL MEDI
3333 BURNET AVENUECINCINATTIOH452093108339363$55,000ACCRUALRESEARCH GRANT
CLEVELAND CLINIC FOUNDATION
9500 EUCLID AVENUECLEVELANDOH441959121530733$200,000ACCRUALRESEARCH GRANT
COLD SPRING HARBOR LABORATORY
1 BUNGTOWN ROADCOLD SPRING HARBORNY117241120133033$110,000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 WEST 168TH STREET BOX 49NEW YORKNY100321355980933$55,000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 WEST 168TH STREET BOX 49NEW YORKNY100321355980933$200,000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 WEST 168TH STREET BOX 49NEW YORKNY100321355980933$200,000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 WEST 168TH STREET BOX 49NEW YORKNY100321355980933$200,000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 WEST 168TH STREET BOX 49NEW YORKNY100321355980933$55,000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 WEST 168TH STREET BOX 49NEW YORKNY100321355980933$200,000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 WEST 168TH STREET BOX 49NEW YORKNY100321355980933$55,000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 WEST 168TH STREET BOX 49NEW YORKNY100321355980933$110,000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 WEST 168TH STREET BOX 49NEW YORKNY100321355980933$400,000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$110,000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$55,000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$110,000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$1,250,000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$65,000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$288,909ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$110,000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$55,000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$200,000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$200,000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$136,605ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$55,000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$110,000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$15,477ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$200,000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$110,000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$110,000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$110,000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$200,000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$55,000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA022150422630403$400,000ACCRUALRESEARCH GRANT
DANA FARBER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$194,425FMVTHERAPY ACCELERATION
DANA FARBER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$194,425FMVTHERAPY ACCELERATION
DUKE UNIVERSITY MEDICAL CENTER
134 CHAPEL DRIVEDURHAMNC277085605321293$200,000ACCRUALRESEARCH GRANT
DUKE UNIVERSITY MEDICAL CENTER
134 CHAPEL DRIVEDURHAMNC277085605321293$200,000ACCRUALRESEARCH GRANT
DUKE UNIVERSITY MEDICAL CENTER
SPONSORED PROGRAMS 324 BLACKWELL SDURHAMNC277085605321293$398,985ACCRUALRESEARCH GRANT
EMORY UNIVERSITY
PO BOX 935084ALTANTAGA311935805662563$250,000FMVTHERAPY ACCELERATION
FOX CHASE CANCER CENTER
333 COTTMAN AVENUEPHILADELPHIAPA1911124342320030723$200,000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVENUE NORTH J6-500SEATTLEWA9810910242371560713$55,000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVENUE NORTH J6-500SEATTLEWA9810910242371560713$55,000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVENUE NORTH J6-500SEATTLEWA9810910242371560713$133,333ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVENUE NORTH J6-500SEATTLEWA9810910242371560713$110,000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVENUE NORTH J6-500SEATTLEWA9810910242371560713$200,000ACCRUALRESEARCH GRANT
HARVARD UNIVERSITY
25 SHATTUCK STREET ROOM 509BOSTONMA021150421035803$55,000ACCRUALRESEARCH GRANT
HARVARD UNIVERSITY
25 SHATTUCK STREET ROOM 509BOSTONMA021150421035803$55,000ACCRUALRESEARCH GRANT
HOSPITAL FOR SPECIAL SURGERY
535 E 70TH STREETNEW YORKNY100211367147493$200,000ACCRUALRESEARCH GRANT
IMMUNE DISEASE INSTITUTE (FKA) THE
3 BLACKFAN CIRCLE CLSB 3RD FLOORBOSTONMA021150421585203$1,250,000ACCRUALRESEARCH GRANT
INDIANA UNIVERSITY (INDIANAPOLIS)
980 INDIANA AVENUE LOCKEFIELD 2232INDIANAPOLISIN4620229153560016733$110,000ACCRUALRESEARCH GRANT
INDIANA UNIVERSITY-PURDUE UNIVERSIT
980 INDIANA AVENUE LOCKEFIELD 2232INDIANAPOLISIN4620229153560016733$133,333ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
1300 YORK AVENUE BOX 89NEW YORKNY1006548051316239783$200,000ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
1300 YORK AVENUE BOX 89NEW YORKNY1006548051316239783$200,000ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
1300 YORK AVENUE BOX 89NEW YORKNY1006548051316239783$200,000ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
1300 YORK AVENUE BOX 89NEW YORKNY1006548051316239783$200,000ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
1300 YORK AVENUE BOX 89NEW YORKNY1006548051316239783$110,000ACCRUALRESEARCH GRANT
JOHNS HOPKINS UNIVERSITY SCHOOL OF
JOHNS HOPKINS UNIVERSITY CENTRAL LOCHICAGOIL606935205951103$65,000ACCRUALRESEARCH GRANT
JOHNS HOPKINS UNIVERSITY SCHOOL OF
JOHNS HOPKINS UNIVERSITY CENTRAL LOCHICAGOIL606935205951103$200,000ACCRUALRESEARCH GRANT
JOHNS HOPKINS UNIVERSITY SCHOOL OF
JOHNS HOPKINS UNIVERSITY CENTRAL LOCHICAGOIL606935205951103$110,000ACCRUALRESEARCH GRANT
JOHNS HOPKINS UNIVERSITY SCHOOL OF
JOHNS HOPKINS UNIVERSITY CENTRAL LOCHICAGOIL606935205951103$55,000ACCRUALRESEARCH GRANT
JOHNS HOPKINS UNIVERSITY SCHOOL OF
JOHNS HOPKINS UNIVERSITY CENTRAL LOCHICAGOIL606935205951103$277,750ACCRUALRESEARCH GRANT
LA JOLLA INSTITUTE FOR ALLERGY AND
9420 ATHENA CIRCLELA JOLLACA920373303286883$200,000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
55 FRUIT STREETBOSTONMA021140415646553$200,000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
55 FRUIT STREETBOSTONMA021140415646553$110,000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
55 FRUIT STREETBOSTONMA021140415646553$110,000ACCRUALRESEARCH GRANT
MASSACHUSETTS INSTITUTE OF TECHNOLO
77 MASSACHUSETTS AVENUECAMBRIDGEMA021390421035943$55,000ACCRUALRESEARCH GRANT
MASSCHUSETTS GENERAL HOSPITAL
55 FRUIT STREETBOSTONMA021140415646553$356,484ACCRUALRESEARCH GRANT
MAYO CLINIC ARIZONA
13400 EAST SHEA BLVDSCOTTSDALEAZ852594160117023$200,000ACCRUALRESEARCH GRANT
MAYO CLINIC ARIZONA
13400 EAST SHEA BLVDSCOTTSDALEAZ852594160117023$110,000ACCRUALRESEARCH GRANT
MAYO CLINIC ROCHESTER
200 FIRST STREET SWROCHESTERMN559054160117023$300,000ACCRUALRESEARCH GRANT
MAYO CLINIC ROCHESTER
200 FIRST STREET SWROCHESTERMN559054160117023$110,000ACCRUALRESEARCH GRANT
MAYO CLINIC ROCHESTER
200 FIRST STREET SWROCHESTERMN559054160117023$320,258ACCRUALRESEARCH GRANT
MEMORIAL SLOAN-KETTERING CANCER CEN
PO BOX 26338NEW YORKNY100871319242363$65,000ACCRUALRESEARCH GRANT
MOFFITT CANCER CENTER AND RESEARCH
12902 MAGNOLIA DRIVETAMPAFL336125932386363$200,000ACCRUALRESEARCH GRANT
MOFFITT CANCER CENTER AND RESEARCH
12902 MAGNOLIA DRIVETAMPAFL336125932386363$65,000ACCRUALRESEARCH GRANT
MOUNT SINAI SCHOOL OF MEDICINE
ICAHN SCHOOL OF MEDICINE AT MOUNT SNEW YORKNY1002965741361711973$110,000ACCRUALRESEARCH GRANT
MOUNT SINAI SCHOOL OF MEDICINE
ICAHN SCHOOL OF MEDICINE AT MOUNT SNEW YORKNY1002965741361711973$110,000ACCRUALRESEARCH GRANT
NEW YORK UNIVERSITY SCHOOL OF MEDIC
545 FIRST AVENUE GBH SC1-55NEW YORKNY100161355623083$200,000ACCRUALRESEARCH GRANT
NEW YORK UNIVERSITY SCHOOL OF MEDIC
545 FIRST AVENUE GBH SC1-55NEW YORKNY100161355623083$1,250,000ACCRUALRESEARCH GRANT
NEW YORK UNIVERSITY SCHOOL OF MEDIC
545 FIRST AVENUE GBH SC1-55NEW YORKNY100161355623083$65,000ACCRUALRESEARCH GRANT
NORTHWESTERN UNIVERSITY
ASRSP 633 CLARK ROOM G547EVANSTONIL602083621678173$200,000ACCRUALRESEARCH GRANT
NORTHWESTERN UNIVERSITY
ASRSP 633 CLARK ROOM G547EVANSTONIL602083621678173$300,000ACCRUALRESEARCH GRANT
NORTHWESTERN UNIVERSITY
ASRSP 633 CLARK ROOM G547EVANSTONIL602083621678173$200,000ACCRUALRESEARCH GRANT
NORTHWESTERN UNIVERSITY
ASRSP 633 CLARK ROOM G547EVANSTONIL602083621678173$1,250,000ACCRUALRESEARCH GRANT
NORTHWESTERN UNIVERSITY
ASRSP 633 CLARK ROOM G547EVANSTONIL602083621678173$133,333ACCRUALRESEARCH GRANT
OHIO STATE UNIVERSITY
1960 KENNY ROADCOLUMBUSOH432103160259863$200,000ACCRUALRESEARCH GRANT
OHIO STATE UNIVERSITY
1960 KENNY ROADCOLUMBUSOH432103160259863$300,000ACCRUALRESEARCH GRANT
OHIO STATE UNIVERSITY
1960 KENNY ROADCOLUMBUSOH432103160259863$110,000ACCRUALRESEARCH GRANT
OHIO STATE UNIVERSITY
1960 KENNY ROADCOLUMBUSOH432103160259863$65,000ACCRUALRESEARCH GRANT
OREGON HEALTH & SCIENCE UNIVER
0690 SW BANCROFT STPORTLANDOR972399311761093$1,111,000FMVTHERAPY ACCELERATION
OREGON HEALTH & SCIENCE UNIVER
0690 SW BANCROFT STPORTLANDOR972399311761093$555,500FMVTHERAPY ACCELERATION
OREGON HEALTH & SCIENCE UNIVERSITY
3181 SW SAM JACKSON PARK ROAD MAILPORTLANDOR972399311761093$55,000ACCRUALRESEARCH GRANT
PRESIDENT & FELLOWS OF HARVARD COLL
6TH FLOOR HOLYOKE CENTER 1350 MASCAMBRIDGEMA021380421035803$55,000ACCRUALRESEARCH GRANT
PRESIDENT & FELLOWS OF HARVARD COLL
6TH FLOOR HOLYOKE CENTER 1350 MASCAMBRIDGEMA021380421035803$65,000ACCRUALRESEARCH GRANT
PRESIDENT & FELLOWS OF HARVARD COLL
6TH FLOOR HOLYOKE CENTER 1350 MASCAMBRIDGEMA021380421035803$200,000ACCRUALRESEARCH GRANT
REGENTS OF THE UNIV OF MICHIGAN
BOX 223131PITTSBURGHPA152513860063093$157,433FMVTHERAPY ACCELERATION
REGENTS OF THE UNIV OF MICHIGAN
BOX 223131PITTSBURGHPA152513860063093$292,835FMVTHERAPY ACCELERATION
REGENTS OF THE UNIV OF MICHIGAN
BOX 223131PITTSBURGHPA152513860063093$238,915FMVTHERAPY ACCELERATION
REGENTS OF THE UNIVERSITY OF MINNES
450 MCNAMARA ALUMNI CENTER 200 OAKMINNEAPOLISMN554554160075133$200,000ACCRUALRESEARCH GRANT
RHODE ISLAND HOSPITAL
593 EDDY STREET ALDRICH 3-317PROVIDENCERI029030502589543$65,000ACCRUALRESEARCH GRANT
ROCKEFELLER UNIVERSITY
1230 YORK AVENUENEW YORKNY100211316241583$55,000ACCRUALRESEARCH GRANT
ROCKEFELLER UNIVERSITY
1230 YORK AVENUENEW YORKNY100211316241583$55,000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
PO BOX 26338NEW YORKNY100871319242363$110,000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
PO BOX 26338NEW YORKNY100871319242363$200,000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
PO BOX 26338NEW YORKNY100871319242363$55,000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
PO BOX 26338NEW YORKNY100871319242363$55,000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
PO BOX 26338NEW YORKNY100871319242363$110,000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
PO BOX 26338NEW YORKNY100871319242363$110,000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
PO BOX 26338NEW YORKNY100871319242363$200,000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
PO BOX 26338NEW YORKNY100871319242363$55,000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
PO BOX 26338NEW YORKNY100871319242363$200,000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
PO BOX 26338NEW YORKNY100871319242363$55,000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
PO BOX 26338NEW YORKNY100871319242363$110,000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
PO BOX 26338NEW YORKNY100871319242363$65,000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
PO BOX 26338NEW YORKNY100871319242363$110,000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
PO BOX 26338NEW YORKNY100871319242363$110,000ACCRUALRESEARCH GRANT
ST JUDE CHILDREN'S RESEARCH HOSPIT
332 N LAUDERFDALEMEMPHISTN381056206460123$110,000ACCRUALRESEARCH GRANT
STANFORD UNIVERSITY
PO BOX 44253SAN FRANCISCOCA941449411563653$108,692FMVTHERAPY ACCELERATION
STANFORD UNIVERSITY
PO BOX 44253SAN FRANCISCOCA941449411563653$333,000FMVTHERAPY ACCELERATION
STOWERS INSTITUTE FOR MEDICAL RESEA
1000 EAST 50TH STREETKANSAS CITYMO641102029935093$55,000ACCRUALRESEARCH GRANT
SUNY UPSTATE MEDICAL UNIVERSITY
4283 WEISKOTTEN HALL 750 EAST ADAMSYRACUSENY132101660387033$110,000ACCRUALRESEARCH GRANT
TEMPLE UNIVERSITY
3307 NORTH BROAD STREETPHILADELPHIAPA191402313659713$400,000ACCRUALRESEARCH GRANT
THE BOARD OF REGENTS OF THE UNIVERS
21 N PARK ST SUITE 6401MADISONWI5371512183960064923$215,000ACCRUALRESEARCH GRANT
THE BOARD OF REGENTS OF THE UNIVERS
21 N PARK ST SUITE 6401MADISONWI5371512183960064923$110,000ACCRUALRESEARCH GRANT
THE BOARD OF TRUSTEES OF THE LELAND
3160 PORTER DRIVE SUITE 100PALO ALTOCA943049411563653$55,000ACCRUALRESEARCH GRANT
THE BOARD OF TRUSTEES OF THE LELAND
3160 PORTER DRIVE SUITE 100PALO ALTOCA943049411563653$65,000ACCRUALRESEARCH GRANT
THE BOARD OF TRUSTEES OF THE LELAND
3160 PORTER DRIVE SUITE 100PALO ALTOCA943049411563653$65,000ACCRUALRESEARCH GRANT
THE BOARD OF TRUSTEES OF THE LELAND
3160 PORTER DRIVE SUITE 100PALO ALTOCA943049411563653$65,000ACCRUALRESEARCH GRANT
THE BOARD OF TRUSTEES OF THE LELAND
3160 PORTER DRIVE SUITE 100PALO ALTOCA943049411563653$268,353ACCRUALRESEARCH GRANT
THE BOARD OF TRUSTEES OF THE LELAND
3160 PORTER DRIVE SUITE 100PALO ALTOCA943049411563653$55,000ACCRUALRESEARCH GRANT
THE BOARD OF TRUSTEES OF THE LELAND
3160 PORTER DRIVE SUITE 100PALO ALTOCA943049411563653$110,000ACCRUALRESEARCH GRANT
THE BOARD OF TRUSTEES OF THE LELAND
3160 PORTER DRIVE SUITE 100PALO ALTOCA943049411563653$110,000ACCRUALRESEARCH GRANT
THE CHILDREN'S HOSPITAL BOSTON
300 LONGWOOD AVENUEBOSTONMA021150427744413$110,000ACCRUALRESEARCH GRANT
THE JOHNS HOPKINS UNIVERSITY SCHOOL
JOHNS HOPKINS UNIVERSITY CENTRAL LOCHICAGOIL606935205951103$200,000ACCRUALRESEARCH GRANT
THE JOHNS HOPKINS UNIVERSITY SCHOOL
JOHNS HOPKINS UNIVERSITY CENTRAL LOCHICAGOIL606935205951103$299,116ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
2150 SHATTUCK AVENUE SUITE 313BERKELEYCA9470459409460021233$65,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
11000 KINROSS AVENUE SUITE 102LOS ANGELESCA900959560061433$110,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
11000 KINROSS AVENUE SUITE 102LOS ANGELESCA900959560061433$200,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
9500 GILMAN DRIVE MC 0009LA JOLLACA9209300099560061443$55,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
9500 GILMAN DRIVE MC 0009LA JOLLACA9209300099560061443$110,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
9500 GILMAN DRIVE MC 0009LA JOLLACA9209300099560061443$1,250,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
9500 GILMAN DRIVE MC 0009LA JOLLACA9209300099560061443$110,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
9500 GILMAN DRIVE MC 0009LA JOLLACA9209300099560061443$110,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
9500 GILMAN DRIVE MC 0009LA JOLLACA9209300099560061443$398,208ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
3333 CALIFRORNIA ST SUITE 315SAN FRANCISCOCA9414309629460364933$110,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
3333 CALIFRORNIA ST SUITE 315SAN FRANCISCOCA9414309629460364933$200,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
3333 CALIFRORNIA ST SUITE 315SAN FRANCISCOCA9414309629460364933$55,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
3333 CALIFRORNIA ST SUITE 315SAN FRANCISCOCA9414309629460364933$110,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
3333 CALIFRORNIA ST SUITE 315SAN FRANCISCOCA9414309629460364933$55,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
3333 CALIFRORNIA ST SUITE 315SAN FRANCISCOCA9414309629460364933$200,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
3333 CALIFRORNIA ST SUITE 315SAN FRANCISCOCA9414309629460364933$55,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
3333 CALIFRORNIA ST SUITE 315SAN FRANCISCOCA9414309629460364933$65,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
3333 CALIFRORNIA ST SUITE 315SAN FRANCISCOCA9414309629460364933$200,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
3333 CALIFRORNIA ST SUITE 315SAN FRANCISCOCA9414309629460364933$110,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
3333 CALIFRORNIA ST SUITE 315SAN FRANCISCOCA9414309629460364933$200,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
3003 S STATE STANN ARBORMI4810912743860063093$200,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
3003 S STATE STANN ARBORMI4810912743860063093$110,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
3003 S STATE STANN ARBORMI4810912743860063093$200,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
3003 S STATE STANN ARBORMI4810912743860063093$110,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
3003 S STATE STANN ARBORMI4810912743860063093$200,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
3003 S STATE STANN ARBORMI4810912743860063093$110,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
3003 S STATE STANN ARBORMI4810912743860063093$200,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
3003 S STATE STANN ARBORMI4810912743860063093$110,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
3003 S STATE STANN ARBORMI4810912743860063093$300,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
3003 S STATE STANN ARBORMI4810912743860063093$110,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
3003 S STATE STANN ARBORMI4810912743860063093$400,000ACCRUALRESEARCH GRANT
THE SCRIPPS RESEARCH INSTITUTE
10550 NORTH TORREY PINES ROAD TPC-LA JOLLACA920373304359543$55,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF COLUMBIA UNIVERSITY
630 WEST 168TH STREET BOX 49NEW YORKNY100321355980933$110,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF THE UNIVERSITY OF P
3451 WALNUT STREET ROOM P-221PHILADELPHIAPA1910462052313526853$200,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF THE UNIVERSITY OF P
3451 WALNUT STREET ROOM P-221PHILADELPHIAPA1910462052313526853$55,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF CHICAGO
6030 S ELLIS AVENUE ROOM 114 ED-CHICAGOIL606373621771393$200,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF CHICAGO
6030 S ELLIS AVENUE ROOM 114 ED-CHICAGOIL606373621771393$55,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF NORTH CAROLINA AT
104 AIRPORT DRIVE SUITE 2200 CB 1CHAPEL HILLNC2759913505660013933$200,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF NORTH CAROLINA AT
104 AIRPORT DRIVE SUITE 2200 CB 1CHAPEL HILLNC2759913505660013933$402,524ACCRUALRESEARCH GRANT
THE UNIVERSITY OF TEXAS MD ANDERSON
1515 HOLCOMBE BLVD UNIT 904HOUSTONTX770307460011183$200,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF TEXAS MD ANDERSON
1515 HOLCOMBE BLVD UNIT 904HOUSTONTX770307460011183$110,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF TEXAS MD ANDERSON
1515 HOLCOMBE BLVD UNIT 904HOUSTONTX770307460011183$110,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF TEXAS MD ANDERSON
1515 HOLCOMBE BLVD UNIT 904HOUSTONTX770307460011183$110,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF TEXAS MD ANDERSON
1515 HOLCOMBE BLVD UNIT 904HOUSTONTX770307460011183$110,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF TEXAS MD ANDERSON
1515 HOLCOMBE BLVD UNIT 904HOUSTONTX770307460011183$200,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF TEXAS MD ANDERSON
1515 HOLCOMBE BLVD UNIT 904HOUSTONTX770307460011183$200,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF TEXAS MD ANDERSON
1515 HOLCOMBE BLVD UNIT 904HOUSTONTX770307460011183$200,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF TEXAS MD ANDERSON
1515 HOLCOMBE BLVD UNIT 904HOUSTONTX770307460011183$400,000ACCRUALRESEARCH GRANT
UNIVERSITY OF ALABAMA AT BIRMINGHAM
1530 3RD AVE SOUTH SUITE 1170 ABBIRMINGHAMAL3529401116360053963$300,000ACCRUALRESEARCH GRANT
UNIVERSITY OF ALABAMA AT BIRMINGHAM
1530 3RD AVE SOUTH SUITE 1170 ABBIRMINGHAMAL3529401116360053963$110,000ACCRUALRESEARCH GRANT
UNIVERSITY OF CALIFORNIA SAN DIEGO
9500 GILMAN DRIVE MC 0009LA JOLLACA9209300099528724943$55,000ACCRUALRESEARCH GRANT
UNIVERSITY OF CALIFORNIA SAN FRANC
3333 CALIFRORNIA ST SUITE 315SAN FRANCISCOCA9414309629460364933$55,000ACCRUALRESEARCH GRANT
UNIVERSITY OF CALIFORNIA SAN FRANC
3333 CALIFRORNIA ST SUITE 315SAN FRANCISCOCA9414309629460364933$55,000ACCRUALRESEARCH GRANT
UNIVERSITY OF CALIFORNIA SAN FRANC
3333 CALIFRORNIA ST SUITE 315SAN FRANCISCOCA9414309629460364933$1,250,000ACCRUALRESEARCH GRANT
UNIVERSITY OF COLORADO DENVER
PO BOX 910238DENVERCO802918460005553$75,000FMVTHERAPY ACCELERATION
UNIVERSITY OF COLORADO DENVER ANSC
ANSCHUTZ MEDICAL CAMPUS BLDG 500 RAURORACO800458401667603$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF CONNECTICUT HEALTH CE
263 FARMINGTON AVENUEFARMINGTONCT0603028065717255433$337,033ACCRUALRESEARCH GRANT
UNIVERSITY OF FLORIDA
RESEARCH GRADUATE PROGRAMS 219 GGAINESVILLEFL326105960020523$110,000ACCRUALRESEARCH GRANT
UNIVERSITY OF FLORIDA
RESEARCH GRADUATE PROGRAMS 219 GGAINESVILLEFL326105960020523$379,475ACCRUALRESEARCH GRANT
UNIVERSITY OF MARYLAND
3112 LEE BUIDLINGCOLLEGE PARKMD207425260020333$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MARYLAND BALTIMORE
RESEARCH ADMINISTRATION SUITE N9E1BALTIMOREMD212015260020333$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MASSACHUSETTS MEDICAL
OFFICE OF RESEARCH RESEARCH FUNDINWORCESTERMA016550431673523$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MASSACHUSETTS MEDICAL
OFFICE OF RESEARCH RESEARCH FUNDINWORCESTERMA016550431673523$110,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MASSACHUSETTS MEDICAL
OFFICE OF RESEARCH RESEARCH FUNDINWORCESTERMA016550431673523$110,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MASSACHUSETTS MEDICAL
OFFICE OF RESEARCH RESEARCH FUNDINWORCESTERMA016550431673523$55,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MASSACHUSETTS MEDICAL
OFFICE OF RESEARCH RESEARCH FUNDINWORCESTERMA016550431673523$110,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MASSACHUSETTS MEDICAL
OFFICE OF RESEARCH RESEARCH FUNDINWORCESTERMA016550431673523$55,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MINNESOTA TWIN CITIE
OFFICE OF SPONSORED PROJECTS ADMINIMINNEAPOLISMN554554160075133$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF NEBRASKA MEDICAL CENT
985100 NEBRASKA MEDICAL CENTEROMAHANE6819851004700491233$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF NORTH CAROLINA AT CHA
104 AIRPORT DRIVE SUITE 2200 CB 1CHAPEL HILLNC2759913505660013933$65,000ACCRUALRESEARCH GRANT
UNIVERSITY OF PENNSYLVANIA
3451 WALNUT STREET ROOM P-221PHILADELPHIAPA1910462052313526853$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF PENNSYLVANIA - SCHOOL
295 JOHN MORGAN BUILDING 3620 HAMIPHILADELPHIAPA191042313526853$110,000ACCRUALRESEARCH GRANT
UNIVERSITY OF ROCHESTER
OFFICE OF RESEARCH PROJECT ADMINIROCHESTERNY146271607432093$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF SOUTH CAROLINA
901 SUMTER STREET 5TH FLCOLUMBIASC292085760011533$21,945ACCRUALRESEARCH GRANT
UNIVERSITY OF SOUTHERN CALIFORNIA
2250 ALCAZAR STREET CONTRACTS GRLOS ANGELESCA900339516423943$65,000ACCRUALRESEARCH GRANT
UNIVERSITY OF SOUTHERN CALIFORNIA
2250 ALCAZAR STREET CONTRACTS GRLOS ANGELESCA900339516423943$400,000ACCRUALRESEARCH GRANT
UNIVERSITY OF TEXAS SOUTHWESTERN ME
5323 HARRY HINES BLVDDALLASTX7539090207560028683$110,000ACCRUALRESEARCH GRANT
UNIVERSITY OF TEXAS SOUTHWESTERN ME
5323 HARRY HINES BLVDDALLASTX7539090207560028693$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF UTAH
201 S PRESIDENTS CIRCLE RM 145SALT LAKE CITYUT8411290038760005253$352,404ACCRUALRESEARCH GRANT
UNIVERSITY OF UTAH
201 S PRESIDENTS CIRCLE RM 145SALT LAKE CITYUT8411290038760005253$65,000ACCRUALRESEARCH GRANT
UNIVERSITY OF VIRGINIA
DIRECTOR OFFICE OF SPONSORED PROGRACHARLOTTESVILLEVA229042371734113$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF WASHINGTON
UW GRANTS CONTRACT SERVICES 3935SEATTLEWA981959430794323$55,000ACCRUALRESEARCH GRANT
UNIVERSITY OF WASHINGTON
UW GRANTS CONTRACT SERVICES 3935SEATTLEWA981959430794323$200,000ACCRUALRESEARCH GRANT
VANDERBILT UNIVERSITY MEDICAL CENTE
3319 WEST END AVENUE SUITE 800NASHVILLETN372326204768223$110,000ACCRUALRESEARCH GRANT
VIRGINIA COMMONWEALTH UNIVERSITY
SPONSORED PROGRAMS ADMINISTRATIONRICHMONDVA2329805680122017613$200,000ACCRUALRESEARCH GRANT
WAKE FOREST UNIVERSITY
CONTROLLERS OFFICE MEDICAL CENTERWINSTONSALEMNC271575605321383$200,000ACCRUALRESEARCH GRANT
WASHINGTON UNIVERSITY SCHOOL OF MED
SPONSORED PROJECTS ACCOUNTING 700ST LOUISMO631104306536113$110,000ACCRUALRESEARCH GRANT
WASHINGTON UNIVERSITY SCHOOL OF MED
SPONSORED PROJECTS ACCOUNTING 700ST LOUISMO631104306536113$399,756ACCRUALRESEARCH GRANT
WEILL CORNELL MEDICAL COLLEGE
1300 YORK AVENUE BOX 89NEW YORKNY1006548051316239783$383,867ACCRUALRESEARCH GRANT
WEILL MED COLLEGE OF CORNELL
1300 YORK AVENEW YORKNY100651316239783$600,000FMVTHERAPY ACCELERATION
WHITEHEAD INSTITUTE FOR BIOMEDICAL
9 CAMBRIDGE CENTERCAMBRIDGEMA0214214790610434123$110,000ACCRUALRESEARCH GRANT
WHITEHEAD INSTITUTE FOR BIOMEDICAL
9 CAMBRIDGE CENTERCAMBRIDGEMA0214214790610434123$55,000ACCRUALRESEARCH GRANT
YALE UNIVERSITY
OFFICE OF SPONSORED PROJECTS PO BONEW HAVENCT0652083270606469733$55,000ACCRUALRESEARCH GRANT
CELATOR PHARMACEUTICALS INC
200 PRINCETON SOUTH CORPORATE CENTEEWINGNJ08628202680869$274,256FMVTHERAPY ACCELERATION
CELATOR PHARMACEUTICALS INC
200 PRINCETON SOUTH CORPORATE CENTEEWINGNJ08628202680869$900,000FMVTHERAPY ACCELERATION
CONSTELLATION PHARMACEUTICALS
215 FIRST STREETCAMBRIDGEMA02142261741721$775,000FMVTHERAPY ACCELERATION
CONSTELLATION PHARMACEUTICALS
215 FIRST STREETCAMBRIDGEMA02142261741721$775,000FMVTHERAPY ACCELERATION
FOX CHASE CANCER CENTER
604 COTTMAN AVECHELTENHAMPA19012231352156$29,000FMVTHERAPY ACCELERATION
GOODWIN PROCTER LLP
53 STATE STREETBOSTONMA02109041378465$345,000FMVTHERAPY ACCELERATION
GOODWIN PROCTOR LLP
53 STATE STREETBOSTONMA02109041378465$345,000FMVTHERAPY ACCELERATION
MILESTONE1 KITE PHARMA
2225 COLORADO AVESANTA MONICACA90404271524986$500,000FMVTHERAPY ACCELERATION
NANOSYN INC
3100 CENTRAL EXPRESSWAYSANTA CLARACA95051860909295$264,490FMVTHERAPY ACCELERATION
STEMLINE THERAPEUTICS INC
750 LEXINGTON AVENEW YORKNY10022450522567$500,000FMVTHERAPY ACCELERATION
STEMLINE THERAPEUTICS INC
750 LEXINGTON AVENEW YORKNY10022450522567$1,000,000FMVTHERAPY ACCELERATION
VALOR BIOTHERAPEUTICS
8800 HSC PARKWAYBRYANTX77807461883738$100,000FMVTHERAPY ACCELERATION
VALOR BIOTHERAPEUTICS
8800 HSC PARKWAYBRYANTX77807461883738$200,000FMVTHERAPY ACCELERATION
VALOR BIOTHERAPEUTICS
8800 HSC PARKWAYBRYANTX77807461883738$100,000FMVTHERAPY ACCELERATION
VALOR BIOTHERAPEUTICS
8800 HSC PARKWAYBRYANTX77807461883738$200,000FMVTHERAPY ACCELERATION
VALOR BIOTHERAPEUTICS
8800 HSC PARKWAYBRYANTX77807461883738$1,000,000FMVTHERAPY ACCELERATION
VELESCO PHARMACEUTICAL SERVICE
46701 N COMMERCE CENTER DRIVEPLYMOUTHMI48170261330932$22,920FMVTHERAPY ACCELERATION
VELESCO PHARMACEUTICAL SERVICE
46701 N COMMERCE CENTER DRIVEPLYMOUTHMI48170261330932$20,219FMVTHERAPY ACCELERATION
VELESCO PHARMACEUTICAL SERVICE
46701 N COMMERCE CENTER DRIVEPLYMOUTHMI48170261330932$9,018FMVTHERAPY ACCELERATION
FieldValueIRS element (for citing)
Total501c3 Org102Total501c3OrgCnt
Total Other Org9TotalOtherOrgCnt

Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp (10 entries)

Grant TypeGrantTypeTxtRecipientRecipientCntCash GrantCashGrantAmt
PATIENT FINANCIAL AID808$111,525
COPAY ASSISTANCE CLL2168$3,686,309
COPAY ASSISTANCE LYMPHOMA7746$8,791,634
COPAY ASSISTANCE MDS1603$3,592,561
COPAY ASSISTANCE MYELOMA6658$22,228,870
COPAY ASSISTANCE MANTEL500$1,305,000
COPAY ASSISTANCE CML1191$2,006,405
COAPY ASSISTANCE ALL34$80,550
COPAY ASSISTANCE WALDENST22$114,152
PATIENT TRAVEL ASSISTNCE633$318,255

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE I, PAGE 1, PART I, LINE 2FormAndLineReferenceDesc
ExplanationFIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. PATIENT FINANCIAL AID: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR MANY EXPENSES RELATED TO THEIR TREATMENT. SOMETIMES PATIENTS HAVE TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE TREATMENT EXPENSES. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS HAS ESTABLISHED A PATIENT FINANCIAL AID PROGRAM THAT PROVIDES APPLICANTS, WHO RESIDE IN THE US AND HAVE A BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. CO-PAY ASSISTANCE: PATIENT APPLICATIONS ARE PROCESSED ON A FIRST COME, FIRST SERVED BASIS. ELIGIBLE PATIENTS MUST RESIDE IN THE UNITED STATES OR PUERTO RICO, HAVE A PROGRAM COVERED BLOOD CANCER DIAGNOSIS CONFIRMED BY A PHYSICIAN, MAINTAIN MEDICAL/PRESCRIPTION INSURANCE AND HAVE HOUSEHOLD INCOME AT OR BELOW 500% OF THE US FEDERAL POVERTY LEVEL AS ADJUSTED BY HOUSEHOLD SIZE AND COST OF LIVING INDEX. PATIENTS MUST PROVIDE PROOF OF INSURANCE AND INCOME. QUALIFYING PATIENTS ARE APPROVED FOR A TWELVE MONTH COVERAGE PERIOD. PATIENT TRAVEL ASSISTANCE: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR TRANSPORTATION TO GET TO THEIR PROVIDERS, E.G. DOCTORS, HOSPITALS, TRANSPLANT CENTERS, AND RESEARCH OR CLINICAL TRIAL CENTERS. SOMETIMES PATIENTS HAVE TO TRAVEL OUT-OF-STATE TO GET THEIR PRESCRIBED AND RECOMMENDED TREATMENTS, OFTENTIMES RESULTING IN PATIENTS HAVING TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS ESTABLISHED THE TRAVEL ASSISTANCE PROGRAM WHICH PROVIDES APPLICANTS, WHO ARE US CITIZENS OR PERMANENT RESIDENTS, HAVE AN ANNUAL INCOME AT OR BELOW 500% OF THE FEDERAL POVERTY LEVEL (FPL) AND HAVE A CONFIRMED BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA.ExplanationTxt

Schedule J IRS990ScheduleJ

FieldValueIRS element (for citing)
Compensation CommitteeYes (X)CompensationCommitteeInd
Independent ConsultantYes (X)IndependentConsultantInd
Form990 Of Other OrganizationsYes (X)Form990OfOtherOrganizationsInd
Compensation SurveyYes (X)CompensationSurveyInd
Board Or Committee ApprovalYes (X)BoardOrCommitteeApprovalInd
Severance PaymentYes (true)SeverancePaymentInd
Supplemental Nonqual Rtr PlanYes (true)SupplementalNonqualRtrPlanInd
Equity Based Comp ArrngmfalseEquityBasedCompArrngmInd
Comp Based On Revenue Of Flng OrgfalseCompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related OrgsfalseCompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng OrgfalseCompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd OrgsfalseCompBsdNetEarnsRltdOrgsInd
Any Non Fixed PaymentsYes (true)AnyNonFixedPaymentsInd
Initial Contract ExceptionfalseInitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (11 entries)

TitleTitleTxtBase Compensation Filing OrgBaseCompensationFilingOrgAmtOther Compensation Filing OrgOtherCompensationFilingOrgAmtDeferred Compensation Flng OrgDeferredCompensationFlngOrgAmtNontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmtTotal Compensation Filing OrgTotalCompensationFilingOrgAmtBonus Filing OrganizationBonusFilingOrganizationAmountComp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt
LOUIS J DEGENNARO
PRESIDENT & CEO$433,871$23,963$84,300$28,674$570,808
ROSEMARIE A LOFFREDO
EVP-CAO & CFO$300,560$11,632$10,150$14,666$337,008
GORDON MILLER JR
SVP FINANCE$210,677$9,439$19,400$27,940$267,456
MARK ROITHMAYR
EVP-CHIEF DEVEL OFF$343,206$10,554$17,976$32,057$403,793
GEORGE J OMIROS-TERM APR15
EVP-CHIEF CAMP&FIELD$306,618$11,698$28,111$22,014$368,441
BRIAN ROSEN - TERM FEB15
CHIEF POLICY & ADVOC$255,063$12,547$18,776$10,873$322,259$25,000$5,594
LEE M GREENBERGER
SVP & CHIEF SCIENTIF$272,769$11,397$10,006$32,899$327,071
JEFFREY COMO-TERM DEC14
CHIEF INFORM.OFFICER$81,125$307,345$20,518$1,389$460,377$50,000
LISA STOCKMON - TERM SEPT14
EVP-CHIEF MARK.OFFIC$219,789$59,141$8,750$12,609$300,289$18,749
GABRIELLE URQUHART-TERM JUN15
REGIONAL VP$210,453$1,923$9,653$10,294$257,323$25,000
JOHN E WALTER - TERM FEB14
FORMER PRES & CEO$54,230$785,660$1,458$22,896$864,244$156,240

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
SCHEDULE J, PAGE 1, PART I, LINE 4LOUIS J. DEGENNARO 0 50,000 0 JEFFREY COMO-TERM DEC14 130,452 0 0 JOHN E. WALTER - TERM FEB14 592,172 0 0
SCHEDULE J, PAGE 1, PART I, LINE 7BONUSES WERE PAID BASED ON THE ACHIEVEMENT OF THE OVERALL ORGANIZATION'S OPERATING PLAN, EMPLOYEE INDIVIDUAL PERFORMANCE AND OTHER METRICS. BONUSES WERE CAPPED ACCORDING TO LLS'S POLICY. THESE AMOUNTS ARE REPORTED ON SCHEDULE J PART II, COLUMN (B)(II).

Schedule M IRS990ScheduleM

Securities Publicly Traded SecuritiesPubliclyTradedGrp

FieldValueIRS element (for citing)
Non Cash CheckboxYes (X)NonCashCheckboxInd
Contribution141ContributionCnt
Noncash Contributions Rpt F990$969,388NoncashContributionsRptF990Amt
Method Of Determining RevenuesMARKET VALUEMethodOfDeterminingRevenuesTxt

Food Inventory FoodInventoryGrp

FieldValueIRS element (for citing)
Non Cash CheckboxYes (X)NonCashCheckboxInd
Contribution48ContributionCnt

Other Non Cash Contri Table OtherNonCashContriTableGrp (2 entries)

Non Cash CheckboxNonCashCheckboxIndDescDescContributionContributionCnt
Yes (X)PRINTED ITEMS11
Yes (X)VARIOUS48
FieldValueIRS element (for citing)
Any Property That Must Be HeldfalseAnyPropertyThatMustBeHeldInd
Review Process Unusual NC GiftsYes (true)ReviewProcessUnusualNCGiftsInd
Third Parties UsedfalseThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE M, PAGE 2, PART IIFormAndLineReferenceDesc
ExplanationPART I, COLUMN (B) LLS IS REPORTING THE NUMBER OF CONTRIBUTIONS FOR EACH OF THE ITEMS IN PART I, NOT THE NUMBER OF INDIVIDUAL ITEMS. PART I, LINE 33 - EXPLANATION FOR NOT REPORTING REVENUE LLS ONLY RECORDS DONATED SECURITIES AS REVENUE. ALL OTHER ITEMS FOR WHICH COLUMN A IS CHECKED ARE NOT RECORDED AS REVENUE OR EXPENSE BECAUSE THEY WOULD NOT HAVE BEEN PURCHASED HAD THEY NOT BEEN DONATED, AND ARE IMMATERIAL IN AMOUNT RELATIVE TO THE STATEMENTS OF LLS.ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (16 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
FORM 990, PAGE 2, PART III, LINE 4AWE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2015, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 7 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 65 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, AND, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. - ADCETRIS WAS APPROVED IN 2011, AND IN JANUARY 2012. IT IS AN ANTIBODY- DRUG CONJUGATE THAT COMBINES AN ANTI-CD30 ANTIBODY AND THE CYTOTOXIC DRUG MONOMETHYL AURISTATIN E (MMAE). IT IS AN ANTI-NEOPLASTIC AGENT USED IN THE TREATMENT OF HODGKIN LYMPHOMA AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT OR THOSE WHO ARE NOT ELIGIBLE FOR ASCT AFTER FAILURE OF AT LEAST 2 MUTIAGEN CHEMOTHERAPY REGIMENS. ADCETRIS WAS ALSO APPROVED FOR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA WITH FAILURE OF AT LEAST ONE PRIOR TREATMENT. - GAZYVA IS A HUMANIZED MONOCLONAL ANTIBODY USED AS A COMBINATION TREATMENT WITH CHLORAMBUCIL TO TREAT PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. IT WAS APPROVED BY THE FDA IN NOVEMBER 2013 AND BY THE EHA IN JULY 2014. - IMBRUVICA IS AN ORAL SMALL MOLECULE INHIBITOR AGIANST BTK KINASE. IT WAS FIRST APPROVED BY THE US FDA ON NOVEMBER 13, 2013 FOR THE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS WHO HAVE RECIEVED AT LEAST ONE PRIOR TREATMENT. ON FEB. 12, 2014 THE US FDA EXPANDED THE APPROVED USE OF THE DRUG TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ADDITIONALLY, IT RECEIVED FURTHER EXPANSION TO TREAT 17P DELETION IN CLL WITH OR WITHOUT PRIOR THERAPY. - ZYDELIG IS AN ORAL SMALL MOLECULE INHIBITOR THAT BLOCKS THE DELTA ISOFORM OF THE ENZYME PHOSPHOINOSITIDE 3-KINASE. IT WAS APPROVED BY THE FDA IN JULY 2014 TO TREAT RELAPSED/REFRACTORY CLL IN COMBINATION WITH RITUXAN. IT WAS ALSO APPROVED TO USE AS A MONOTHERAPY FOR RELAPSED MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2015, FOR THE FOURTH YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN SIX OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR PATIENTS WITH NON- CUTANEOUS T-CELL LYMPHOPROLIFERATIVE DISORDERS - DEVELOP NOVEL TARGETED THERAPIES FOR CLL PATIENTS, WITH REAL CURATIVE POTENTIAL - DEVELOP NOVEL TREATMENT STRATEGIES FOR MDS AND AML PATIENTS - DEVELOP NOVEL TARGETED THERAPIES FOR PATIENTS WITH HIGH-RISK MYELOMA - DEVELOPMENT OF NEW-TARGETED THERAPIES FOR INDOLENT LYMPHOMA PATIENTS - DEFINE GENETIC/MOLECULAR PREDISPOSITIONS TO LONG-TERM AND LATE-TERM EFFECTS ASSOCIATED WITH STANDARD THERAPIES IN PEDIATRIC ALL AND APPLY THIS INFORMATION TO IMPROVE PATIENT OUTCOMES. THE THERAPY ACCELERATION PROGRAM THIS STRATEGIC INITIATIVE WAS LAUNCHED IN 2007 TO MOVE NEW TREATMENTS AND DIAGNOSTICS THROUGH PRECLINICAL DEVELOPMENT AND CLINICAL TRIALS, FASTER. USING MILESTONE-DRIVEN CONTRACTS AND WORKING IN CONCERT WITH ACADEMIC INVESTIGATORS, MEDICAL CENTERS AND COMPANIES, LLS IS FURTHER BRIDGING THE GAP BETWEEN DISCOVERY AND HUMAN APPLICATIONS TO INCREASE THE LIKELIHOOD THAT NOVEL, POSSIBLY BREAKTHROUGH, TREATMENTS WILL BE AVAILABLE TO PATIENTS AS SOON
FORM 990, PAGE 2, PART III, LINE 4BA NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL; AND CURRENT AND ACCURATE INFORMATION ABOUT SYMPTOMS, RISK FACTORS AND TREATMENT. PUBLICATIONS AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS THROUGH THE INFORMATION RESOURCE CENTER AND LLS CHAPTERS. MANY MATERIALS ARE ALSO AVAILABLE TO VIEW AND DOWNLOAD AT WWW.LLS.ORG/RESOURCECENTER. DOWNLOADABLE MATERIALS ARE AVAILABLE IN ENGLISH, SPANISH AND FRENCH. - 705,326 PRINTED BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS DISTRIBUTED IN 2015. FINANCIAL ASSISTANCE IN 2015, A COMBINED 42,235,261 WAS DISBURSED TO PATIENTS THROUGH THE LLS PATIENT FINANCIAL AID (111,525),CO-PAY ASSISTANCE PROGRAMS (41,805,481) AND THE LLS NATIONAL PATIENT TRAVEL ASSISTANCE PROGRAM (318,255). CO-PAY ASSISTANCE PROGRAM THIS CO-PAY ASSISTANCE PROGRAM HELPS PATIENTS WITH MANY KINDS OF BLOOD CANCERS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO-PAYMENT OBLIGATIONS RELATED TO TREATING THEIR CANCER. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUND AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. FOR MORE INFORMATION CALL, (877) LLS-COPAY (877) 557-2672 OR VISIT WWW.LLS.ORG/COPAY. - 19,922 PATIENTS RECEIVED LLS CO-PAY ASSISTANCE IN 2015 COMMUNITY PROGRAMS EACH LLS CHAPTER OFFICE IS STAFFED WITH A PATIENT SERVICES MANAGER (PSM) WHO OVERSEES SERVICES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PSMS ARE HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING OR SOCIAL WORK. PSMS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS. COMMUNITY-BASED EDUCATION AND OUTREACH, SUPPORT AND PUBLIC POLICY AND ADVOCACY PROGRAMS ARE AVAILABLE. PATIENT EDUCATION PROGRAMS: IN 2015 WE CONDUCTED 221 LOCAL PATIENT EDUCATION PROGRAMS TO A TOTAL OF 9,807 ATTENDEES. THESE PROGRAMS RANGED FROM DISEASE SPECIFIC TOPICS TO THOSE OF SURVIVORSHIP. OF THE TOTAL ATTENDING THESE LOCAL EDUCATION PROGRAMS, A MAJORITY WERE PATIENTS AND CAREGIVERS (6,872 ATTENDEES) BUT IMPORTANTLY, MANY (2,404 ATTENDEES) WERE HEALTHCARE PROFESSIONALS. BLOOD CANCER CONFERENCES: LLS WORKS TO ELEVATE OUR VISIBILITY IN COMMUNITIES WE SERVE BY HOSTING LARGER-SCALE CONFERENCES, GEARED FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. THESE EVENTS ARE A CATALYST FOR BRINGING MANY DEDICATED PEOPLE TOGETHER TO FOCUS ON BLOOD CANCER AWARENESS, INFORMATION AND THE LATEST ADVANCES IN MEDICAL SCIENCE. THEY ARE ALSO AN IMPORTANT SOURCE OF CONTINUING EDUCATION FOR MANY HEALTHCARE PROFESSIONALS. IN 2015, 25 BCC CONFERENCES WERE HELD WITH TOTAL ATTENDANCE OF 6,589. 2,965 WERE PATIENTS, 1,511 CAREGIVERS, 1,001 NURSES, 181 SOCIAL WORKS, 128 MEDICAL DOCTORS, AND 628 "OTHER" HEALTHCARE PROFESSIONALS SERVING THE UNDERSERVED: IN 2015, WE OFFERED 68 SPECIAL PROGRAMS TO PEOPLE WHO OFTEN DON'T HAVE THE SAME ACCESS TO INFORMATION AND SUPPORT AS OTHERS MIGHT HAVE. BREAKING DOWN ACCESS BARRIERS IN UNDERREPRESENTED POPULATIONS MEANS BLOOD CANCER PATIENTS GET THE INFORMATION AND SUPPORT THEY NEED. THIS OUTREACH BROUGHT IMPORTANT DISEASE TREATMENT INFORMATION TO MORE THAN 5,500 PEOPLE IN COMMUNITIES WE SERVE. OF THIS, 3,870 WERE PATIENTS AND CAREGIVERS, JOINED BY 1,126 HEALTHCARE PROFESSIONALS. MYELOPROLIFERATIVE NEOPLASMS OR MPN: IN 2015, LLS WAS ABLE TO OFFER SPECIALIZED MYELOPROLIFERATIVE NEOPLASMS OR MPN EDUCATION PROGRAMS IN FOUR COMMUNITIES TO A TOTAL OF 70 PATIENTS AND CAREGIVERS AND 9 HEALTHCARE PROFESSIONALS. IN ADDITION, LLS PROVIDED COMMUNITY-BASED EDUCATION CONCERNING THE LATEST CLINICAL TRIALS INFORMATION TO 634 PATIENTS AND CAREGIVERS, WHO WERE JOINED BY 286 HEALTHCARE PROFESSIONALS. FAMILY SUPPORT GROUPS: THROUGHOUT THE US, IN 2015, LLS SUPPORTED OR HOSTED 296 REGISTERED FAMILY SUPPORT GROUP MEETINGS FOR PATIENTS AND THEIR FAMILIES. GROUPS ARE GUIDED BY TWO VOLUNTEER ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. LLS SUPPORT GROUPS ARE THE PERFECT PLACE TO TALK WITH OTHER PEOPLE AFFECTED BY BLOOD CANCERS, INCLUDING PATIENTS, FAMILY MEMBERS AND CAREGIVERS. THE GROUPS PROVIDE MUTUAL SUPPORT AND OFFER THE OPPORTUNITY TO DISCUSS ANXIETIES AND CONCERNS WITH OTHERS WHO SHARE THE SAME EXPERIENCES. THIS SHARING STRENGTHENS THE FAMILY BOND AND ENHANCES EVERYONE'S ABILITY TO COPE WITH CANCER. PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM: FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT-VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE NEW PATIENT TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS. - 1,476 FIRST CONNECTIONS ACROSS THE US IN 2015.
FORM 990, PAGE 2, PART III, LINE 4CPATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 9 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. - 31,511 INQUIRIES MADE TO OUR INFORMATION SPECIALISTS, AND 30,871 INQUIRIES MADE TO OUR PATIENT ACCESS STAFF ACROSS THE COUNTRY IN 2015. THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO THEIR LOCATION TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING CO-PAY ASSISTANCE, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH AND SPANISH, AND CLINICAL-TRIAL SEARCHES VIA AN ONLINE CLINICAL- TRIAL SEARCH SERVICE THAT OFFERS PATIENTS AND CAREGIVERS IMMEDIATE ACCESS TO LISTINGS OF BLOOD CANCER CLINICAL TRIALS. PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS CAN INTERACT WITH LLS AND ONE ANOTHER THROUGH SOCIAL NETWORKING, PODCASTS AND ENEWSLETTERS. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS LLS SPONSORS TELEPHONE AND WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES. IN 2015, 9 LLS NATIONAL EDUCATION PROGRAMS FEATURED DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT SUPPORT AND TREATMENT OPTIONS FROM WORLD RENOWNED CLINICAL EXPERTS. OPPORTUNITIES ARE PROVIDED TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. THESE PROGRAMS OFFER CONTINUING EDUCATION CREDITS FOR NURSES AND SOCIAL WORKERS. LLS ALSO SPONSORS A RANGE OF PROFESSIONAL EDUCATION PROGRAMS. RECENT PROGRAMS EXPLORED THE ADMINISTRATION AND MANAGEMENT OF CURRENT THERAPIES FOR HEMATOLOGIC MALIGNANCIES AND COMMUNICATION AMONG PRIMARY CARE PROVIDERS AND HEMATOLOGISTS/ONCOLOGISTS IN MANAGING PATIENTS WITH HEMATOLOGIC CANCER. UPCOMING PROGRAMS ARE POSTED AT WWW.LLS.ORG/PROGRAMS AND ARCHIVES OF PAST PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PASTPROGRAMS. PROFESSIONAL EDUCATION PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PROFESSIONALED. LLS ALSO OFFERS DISEASE-SPECIFIC WEBCASTS PRESENTED BY WORLD RENOWNED CLINICAL EXPERTS. THESE CAN BE ACCESSED AT WWW.LLS.ORG/WEBCASTS.
FORM 990, PAGE 2, PART III, LINE 4DD) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT.
FORM 990, PART V, LINE 4BCANADA
FORM 990, PAGE 6, PART VI, LINE 6THE MEMBERS OF LLS CONSIST OF ONE ELECTED REPRESENTATIVE FROM EACH CHAPTER.
FORM 990, PAGE 6, PART VI, LINE 7ATHE BOARD OF REPRESENTATIVES (REPRESENTING THE CHAPTERS) ELECTS THE MEMBERS OF LLS'S GOVERNING BODY, ITS NATIONAL BOARD OF DIRECTORS.
FORM 990, PAGE 6, PART VI, LINE 7BSIGNIFICANT DECISIONS AFFECTING THE CHAPTERS REQUIRE AN APPROVING VOTE BY THE CHAPTER DELEGATES. DECISIONS NOT SIGNIFICANTLY AFFECTING THE CHAPTERS DO NOT REQUIRE APPROVAL FROM THE CHAPTER DELEGATES.
FORM 990, PAGE 6, PART VI, LINE 11BTHE FORM 990 WAS PREPARED BY THE LLS FINANCE DEPARTMENT AND WAS REVIEWED BY THE CAO & CFO, SR. VICE PRESIDENT OF FINANCE, AND KPMG FOR COMMENT AND SUGGESTED REVISIONS. THE FORM 990 WAS THEN PROVIDED TO THE AUDIT COMMITTEE, WHICH IS A COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWED THE 990 AND PROVIDED INPUT PRIOR TO FILING. THE FINAL DRAFT FORM 990 WAS PROVIDED TO THE ENTIRE BOARD OF DIRECTORS PRIOR TO FILING BY POSTING THE FORM ON AN INTRANET WEBSITE.
FORM 990, PAGE 6, PART VI, LINE 12CALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES MEMBERS, CHAPTER BOARD MEMBERS, FAMILY SUPPORT GROUP FACILITATORS, AND TNT COACHES ARE REQUIRED TO REVIEW THE CONFLICT OF INTEREST POLICY ON AN ANNUAL BASIS AND SUBMIT A SIGNED FORM ACKNOWLEDGING THAT THEY HAVE REVIEWED THE POLICY AND DISCLOSED ANY CONFLICTS OF INTEREST. ALL FORMS ARE COLLECTED AND THE AUDIT COMMITTEE REVIEWS ANY FORMS DISCLOSING A POSSIBLE CONFLICT OF INTEREST AND DETERMINES WHETHER OR NOT A CONFLICT EXISTS. PART VI, LINE 12 C: ALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES ARE RECUSED FROM ANY DISCUSSION WHERE A CONFLICT OF INTEREST EXISTS. ANY QUESTIONS REGARDING COI WILL GO TO THE AUDIT COMMITTEE.
FORM 990, PAGE 6, PART VI, LINE 15ATHE EXECUTIVE COMMITTEE COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS REVIEWS AND MONITORS THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. IN 2015 THE COMMITTEE OBTAINED A SURVEY OF OTHER NOT- FOR-PROFIT ORGANIZATIONS' COMPENSATION RANGES AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE COMMITTEE MET AND REVIEWED THE COMPENSATION PACKAGE BUT IT WAS NOT INCLUDED IN THE COMMITTEE MINUTES.
FORM 990, PAGE 6, PART VI, LINE 15BTHE EXECUTIVE COMMITTEE COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS REVIEWS AND MONITORS THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. IN 2015 THE COMMITTEE OBTAINED A SURVEY OF OTHER NOT- FOR-PROFIT ORGANIZATIONS' COMPENSATION RANGES AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE COMMITTEE MET AND REVIEWED THE COMPENSATION PACKAGE BUT IT WAS NOT INCLUDED IN THE COMMITTEE MINUTES.
FORM 990, PAGE 6, PART VI, LINE 17ILLINOIS, INDIANA, KANSAS, KENTUCKY, LOUISIANA, MASSACHUSETTS, MARYLAND, MAINE, MICHIGAN, MINNESOTA, MISSOURI, MISSISSIPPI, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEBRASKA, NEW YORK, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, PUERTO RICO, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, UTAH, VIRGINIA, WASHINGTON, WISCONSIN, WEST VIRGINIA
FORM 990, PAGE 6, PART VI, LINE 19THE LEUKEMIA & LYMPHOMA SOCIETY, INC. MAKES ITS ANNUAL FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE AT WWW.LLS.ORG. ITS GOVERNING DOCUMENTS ARE MADE AVAILABLE FOR PUBLIC INSPECTION. ANY IDENTIFIED CONFLICTS OF INTEREST ARE DISCLOSED IN THE 990.
FORM 990, PART XI, LINE 9LLS CANADA REVENUE 10,501,177 LLS CANADA GAIN ON INVESTMENT 177,817 LLS CANADA EXPENSES -10,122,744 FOREIGN CURRENCY TRANSLATION -530,316
FORM 990, PART XI, LINE 9CANADA OPENING NET ASSETS ADJUSTMENTS 133,047 FINANCIAL STATEMENTS ROUNDING -61 LLS CANADA CHANGE IN NET ASSET -25,936 INC.

Schedule R IRS990ScheduleR

Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (3 entries)

Address Line1ForeignAddress/AddressLine1TxtCityForeignAddress/CityNmCountryForeignAddress/CountryCdForeign PostalForeignAddress/ForeignPostalCdPrimary ActivitiesPrimaryActivitiesTxtLegal Domicile Foreign CountryLegalDomicileForeignCountryCdBusiness Name Line1DirectControllingEntityName/BusinessNameLine1TxtControlled OrganizationControlledOrganizationIndAddress Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdEINEINLegal Domicile StateLegalDomicileStateCdExempt Code SectionExemptCodeSectionTxtPublic Charity StatusPublicCharityStatusTxt
THE LLS OF CANADA
804 2 LANSING SQUARETORONTOCAM2J4P8PART VIICANAfalse
THE LLS RESEARCH PROGRAMS INC
PART VIILLS INCYes (true)1311 MAMARONECK AVENUEWHITE PLAINSNY10605133470494DE501C311B
THE LLS RESEARCH FOUNDATION
PART VIILLS INCYes (true)1311 MAMARONECK AVENUEWHITE PLAINSNY10605133709252DE501C311B
FieldValueIRS element (for citing)
Receipt Of Int Annts Rnts RyltsfalseReceiptOfIntAnntsRntsRyltsInd
Gift Grnt Or Cap Contri To Oth OrgfalseGiftGrntOrCapContriToOthOrgInd
Gift Grnt Cap Contri From Oth OrgYes (true)GiftGrntCapContriFromOthOrgInd
Loans Or Guarantees To Other OrgYes (true)LoansOrGuaranteesToOtherOrgInd
Loans Or Guarantees From Oth OrgfalseLoansOrGuaranteesFromOthOrgInd
Div Related OrganizationfalseDivRelatedOrganizationInd
Asset Sale To Other OrgfalseAssetSaleToOtherOrgInd
Asset Purchase From Other OrgfalseAssetPurchaseFromOtherOrgInd
Asset ExchangefalseAssetExchangeInd
Rental Of Facilities To Oth OrgfalseRentalOfFacilitiesToOthOrgInd
Rental Of Fclts From Oth OrgfalseRentalOfFcltsFromOthOrgInd
Perform Of Services For Oth OrgfalsePerformOfServicesForOthOrgInd
Perform Of Services By Other OrgfalsePerformOfServicesByOtherOrgInd
Sharing Of FacilitiesYes (true)SharingOfFacilitiesInd
Paid Employees SharingYes (true)PaidEmployeesSharingInd
Reimbursement Paid To Other OrgfalseReimbursementPaidToOtherOrgInd
Reimbursement Paid By Other OrgfalseReimbursementPaidByOtherOrgInd
Transfer To Other OrgfalseTransferToOtherOrgInd
Transfer From Other OrgfalseTransferFromOtherOrgInd

Transactions Related Org TransactionsRelatedOrgGrp (2 entries)

Transaction TypeTransactionTypeTxtInvolvedInvolvedAmtMethod Of Amount DeterminationMethodOfAmountDeterminationTxt
THE LEUKEMIA & LYMPHOMA SOCIETY
D$38,116COST
OF CANADA

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE RFormAndLineReferenceDesc
ExplanationTHE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA CARRIES OUT THE SAME PRIMARY ACTIVITIES AS THE LEUKEMIA & LYMPHOMA SOCIETY, INC., IN CANADA. THE LEUKEMIA SOCIETY RESEARCH PROGRAMS, INC. AND THE LEUKEMIA RESEARCH FOUNDATION, INC. SUPPORT THE ACTIVITIES OF THE LEUKEMIA & LYMPHOMA SOCIETY, INC.ExplanationTxt

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.